Document:

Exhibit 10.3

SPONSOR SUPPORT AGREEMENT

This
SPONSOR SUPPORT AGREEMENT (this “Agreement”), dated as of April 28 2022, is entered into by and among Ignyte
Sponsor LLC, a Delaware limited liability company (the “Sponsor”), Ignyte Acquisition Corp., a Delaware corporation
(“Ignyte”), and Peak Bio Co., Ltd., a corporation organized under the laws of the Republic of Korea (the “Company”).
Capitalized terms used but not otherwise defined in this Agreement shall have the meanings ascribed to them in the BCA (as defined
below).

RECITALS

WHEREAS,
concurrently herewith, Ignyte, the Company, and Ignyte Korea Co., Ltd., a corporation organized under the laws of the Republic
of Korea, are entering into a Business Combination Agreement (as amended, supplemented, restated or otherwise modified from time
to time, the “BCA”), pursuant to which (and subject to the terms and conditions set forth therein) the parties
thereto are agreeing to, among other things, effect the Share Swap, and as a result, the Company will become a wholly-owned subsidiary
of Ignyte;

WHEREAS,
the Sponsor is currently the record owner of 1,437,500 shares of Ignyte Common Stock (the “Sponsor Shares”);
and 

WHEREAS, as a condition and inducement to the willingness of Ignyte and the Company to enter into the BCA, Ignyte,
the Company and the Sponsor are entering into this Agreement.

AGREEMENT

NOW,
THEREFORE, in consideration of the foregoing and the mutual covenants and agreements set forth herein, and for other good
and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, and intending to be legally bound hereby,
the Sponsor, Ignyte and the Company hereby agree as follows:

1. Voting Agreement. The Sponsor agrees that, at the Ignyte
Stockholders’ Meeting, at any other meeting of the stockholders of Ignyte (whether annual or special and whether or not
an adjourned or postponed meeting, however called and including any adjournment or postponement thereof) and in connection with
any written consent of the stockholders of Ignyte, the Sponsor shall:

a. when such meeting is held, appear at such meeting or
otherwise cause the Sponsor Shares to be counted as present thereat for the purpose of establishing a quorum;

b. vote (or execute
and return an action by written consent), or cause to be voted at such meeting (or validly execute and return and cause such consent
to be granted with respect to), all of the Sponsor Shares in favor of (i) the approval and adoption of the BCA and approval of
the Business Combination and all other transactions contemplated by the BCA and (ii) against any action, agreement or transaction
or proposal that would result in a breach of any covenant, representation or warranty or any other obligation or agreement of
Ignyte under the BCA or that would reasonably be expected to result in the failure of the Business Combination from being consummated
and (iii) each of the proposals and any other matters necessary or reasonably requested by Ignyte for consummation of the Business
Combination and the other transactions contemplated by the BCA; and

c. vote (or execute and return an action by written consent),
or cause to be voted at such meeting (or validly execute and return and cause such consent to be granted with respect to), all
of the Sponsor Shares against (i) any Business Combination Proposal other than with the Company and (ii) any other action that
would reasonably be expected to (x) materially impede, interfere with, delay, postpone or adversely affect the Business Combination
or any of the other transactions contemplated by the BCA, or (y) result in a breach of any covenant, representation or warranty
or other obligation or agreement of the Sponsor contained in this Agreement.

2. Transfer of Shares.
Except as otherwise contemplated by the BCA or this Agreement, the Sponsor agrees that it shall not, directly or indirectly, (a)
sell, assign, transfer (including by operation of law), create any lien or pledge, dispose of or otherwise encumber any of the
Sponsor Shares or otherwise agree to do any of the foregoing, (b) deposit any Sponsor Shares into a voting trust or enter into
a voting agreement or arrangement or grant any proxy or power of attorney with respect
thereto that is inconsistent with this Agreement or (c) enter into any contract, option or other arrangement or undertaking requiring
the direct acquisition or sale, assignment, transfer or other disposition of any Sponsor Shares.

1

3.
No Solicitation of Transactions. The Sponsor agrees not to directly or indirectly, through any officer, director, representative,
agent or otherwise, (a) solicit, initiate or knowingly encourage (including by furnishing information) the submission of, or participate
in any discussions or negotiations regarding, any transaction in violation of the BCA or (b) participate in any discussions or
negotiations regarding, or furnish to any person or other entity or “group” within the meaning of Section 13(d) of
the Exchange Act, any information with the intent to, or otherwise cooperate in any way with respect to, or knowingly assist,
participate in, facilitate or encourage, any unsolicited proposal that constitutes, or may reasonably be expected to lead to,
a Business Combination Proposal or other transaction in violation of the BCA. Sponsor shall, and shall cause its affiliates and
Representatives to, immediately cease any and all existing discussions or negotiations with any person (other than with the Company,
its stockholders and their respective affiliates and Representatives) conducted prior to the date hereof with respect to, or which
is reasonably likely to give rise to or result in, a Business Combination Proposal. If the Sponsor receives any inquiry or proposal
with respect to a Business Combination Proposal, then Sponsor shall promptly (and in no event later than twenty-four (24) hours
after the Sponsor becomes aware of such inquiry or proposal) notify such person in writing that Ignyte is subject to an exclusivity
agreement with respect to the Business Combination that prohibits Sponsor from considering such inquiry or proposal.

4.
Representations and Warranties of the Sponsor. The Sponsor hereby represents and warrants to Ignyte and the Company as
follows:

a. The Sponsor is the only record and a beneficial owner (within the meaning of Rule 13d-3 under the Exchange Act) of,
and has good, valid and marketable title to, the Sponsor Shares, free and clear of Liens other than as created by this Agreement
or Sponsor’s organizational documents or the organizational documents of Ignyte (including, without limitation, for the
purposes hereof, any agreement between or among stockholders of Ignyte).

b. The Sponsor (i) has full voting power, full power
of disposition and full power to issue instructions with respect to the matters set forth herein, in each case, with respect to
the Sponsor Shares, (ii) has not entered into any voting agreement or voting trust with respect to any of the Sponsor Shares that
is inconsistent with the Sponsor’s obligations pursuant to this Agreement, (iii) has not granted a proxy or power of attorney
with respect to any of the Sponsor Shares that is inconsistent with the Sponsor’s obligations pursuant to this Agreement
and (iv) has not entered into any agreement or undertaking that is otherwise inconsistent with, or would interfere with, or prohibit
or prevent it from satisfying, its obligations pursuant to this Agreement.

c. The Sponsor (i) is a legal entity duly organized,
validly existing and, to the extent such concept is applicable, in good standing under the Laws of the jurisdiction of its organization
and (ii) has all requisite limited liability company or other power and authority and has taken all limited liability company
or other action necessary in order to, execute, deliver and perform its obligations under this Agreement and to consummate the
transactions contemplated hereby. This Agreement has been duly executed and delivered by the Sponsor and constitutes a valid and
binding agreement of the Sponsor enforceable against the Sponsor in accordance with its terms, subject to applicable bankruptcy,
insolvency, fraudulent conveyance, reorganization, moratorium and similar Laws affecting creditors’ rights generally and
subject, as to enforceability, to general principles of equity.

d. Other than the filings, notices and reports pursuant to, in
compliance with or required to be made under the Exchange Act, no filings, notices, reports, consents, registrations, approvals,
permits, waivers, expirations of waiting periods or authorizations are required to be obtained by the Sponsor from, or to be given
by the Sponsor to, or be made by the Sponsor with, any Governmental Authority in connection with the execution, delivery and performance
by the Sponsor of this Agreement, the consummation of the transactions contemplated hereby or the Business Combination and the
other transactions contemplated by the BCA.

e. The execution, delivery and performance of this Agreement by the Sponsor does not,
and the consummation of the transactions contemplated hereby or the Business Combination and the other transactions contemplated
by the BCA will not, constitute or result in (i) a breach or violation of, or a default under, the limited liability company agreement
or similar governing documents of the Sponsor, (ii) with or without notice, lapse of time or both, a breach or violation of, a
termination (or right of termination) of or a default under, the loss of any benefit under, the creation, modification or acceleration
of any obligations under or the creation of a Lien on any of the properties, rights or assets of the Sponsor pursuant to any contract
binding upon the Sponsor or, assuming (solely with respect to performance of
this Agreement and the transactions contemplated hereby), compliance with the matters referred to in Section 1, under any
applicable Law to which the Sponsor is subject or (iii) any change in the rights or obligations of any party under any contract
legally binding upon the Sponsor, except, in the case of clause (ii) or (iii) directly above, for any such breach, violation,
termination, default, creation, acceleration or change that would not, individually or in the aggregate, reasonably be expected
to prevent or materially delay or impair the Sponsor’s ability to perform its obligations hereunder or to consummate the
transactions contemplated hereby, the consummation of the Business Combination or the other transactions contemplated by the BCA.

2

f. As of the date of this Agreement, there is no action, proceeding or investigation pending against the Sponsor or, to the knowledge
of the Sponsor, threatened against the Sponsor that questions the beneficial or record ownership of the Sponsor Shares, the validity
of this Agreement or the performance by the Sponsor of its obligations under this Agreement.

g. The Sponsor understands and acknowledges
that each of Ignyte and the Company is entering into the BCA in reliance upon the Sponsor’s execution and delivery of this
Agreement and the representations, warranties, covenants and other agreements of the Sponsor contained herein

5. Further Assurances.
From time to time, at either Ignyte’s of the Company’s request and without further consideration, the Sponsor shall
execute and deliver such additional documents and take all such further action as may be reasonably necessary or reasonably requested
to effect the actions and consummate the transactions contemplated by this Agreement.

6.
Changes in Capital Stock. In the event of a stock split, stock dividend or distribution, or any change in Ignyte’s
capital stock by reason of any stock split, reverse stock split, recapitalization, combination, reclassification, exchange of
shares or the like, equitable adjustment shall be made to the provisions of this Agreement as may be required so that the intended
rights, privileges, duties and obligations hereunder shall be given full effect.

7.
Amendment and Modification. This Agreement may not be amended, modified or supplemented in any manner, whether by course
of conduct or otherwise, except by an instrument in writing signed by the Sponsor, Ignyte and the Company.

8.
Waiver. No failure or delay by any party hereto exercising any right, power or privilege hereunder shall operate as a waiver
thereof nor shall any single or partial exercise thereof preclude any other or further exercise thereof or the exercise of any
other right, power or privilege. The rights and remedies of the parties hereto hereunder are cumulative and are not exclusive
of any rights or remedies which they would otherwise have hereunder. Any agreement on the part of a party hereto to any such waiver
shall be valid only if set forth in a written instrument executed and delivered by such party.

9.
Notices. All notices and other communications hereunder shall be in writing and shall be deemed given if delivered personally,
by email (with confirmation of receipt) or sent by a nationally recognized overnight courier service to the parties hereto at
the following addresses (or at such other address for a party as shall be specified by like notice made pursuant to this Section
9):

	 	if to Ignyte, to:	 
	 	 	 	 
	 	Ignyte Acquisition Corp.
 640 Fifth Avenue
 New York, NY	 
	 	Attention:	David Rosenberg,
    Co-Chief Executive Officer 

David J. Strupp, Jr., Co-Chief Executive Officer	 
	 	Email:	drosenberg@Ignytespac.com

    dstrupp@Ignytespac.com	 
	 	 	 	 
	 	with a copy to:

DLA Piper LLP (US)
 51 John F. Kenney Parkway
 Suite 120
 Short Hills, NJ 07078

	 

	 	Attention:	Andrew P. Gilbert; Scott A. Cowan	 
	 	Email:	andrew.gilbert@us.dlapiper.com; scott.cowan@us.dlapiper.com

3

	 	if to the Sponsor, to:	 
	 	 	 
	 	Ignyte Sponsor LLC 

    640 Fifth Avenue

    New York, NY	 
	 	Attention:	David Rosenberg, Co-Chief Executive Officer

    David J. Strupp, Jr., Co-Chief Executive Officer	 
	 	Email:	drosenberg@Ignytespac.com

    dstrupp@Ignytespac.com	 
	 	 	 
	 	if to the Company, to:	 
	 	 	 
	 	Peak Bio Co. Ltd.

    Building B #1009,

    670 Daewangpangyo-ro (Sampyeong-dong, U Space 2),

    Bundang-gu, Seongnam-si, Gyenggi-do

    Attention: Hoyoung Huh, MD, Ph.D., Chief Executive Officer

    Email: hoyoung.huh@ph-pharma.com	 
	 	 	 
	 	with a copy to:	 
	 	 	 
	 	Bae, Kim & Lee LLC

    13F, Tower B, Centropolis,

    26 Ujeongguk-ro, Jongno-gu, Seoul 03161

    Attention: Jung Min Jo

    Email: jungmin.jo@bkl.co.kr	 
	 	 	 
	 	and	 	 
	 	 	 
	 	BC Burr McCabe Law 

    584 Castro Street #882 

    San Francisco, CA 94114 

    Attention: Peter McCabe 

    Email: pmccabe@bcbmlaw.com	 

10.
Entire Agreement. This Agreement and the BCA constitute the entire agreement and supersede all prior agreements and understandings,
both written and oral, among the parties hereto with respect to the subject matter hereof and thereof.

11.
No Third-Party Beneficiaries. The Sponsor hereby agrees that its representations, warranties and covenants set forth herein
are solely for the benefit of Ignyte and the Company in accordance with and subject to the terms of this Agreement, and this Agreement
is not intended to, and does not, confer upon any person other than the parties hereto any rights or remedies hereunder, including,
without limitation, the right to rely upon the representations and warranties set forth herein, and the parties hereto hereby
further agree that this Agreement may only be enforced against, and any action that may be based upon, arise out of or relate
to this Agreement, or the negotiation, execution or performance of this Agreement may only be made against, the persons expressly
named as parties hereto.

12.
Governing Law and Venue.

a. This Agreement shall be governed by, interpreted under, and construed in accordance with the
internal laws of the State of Delaware applicable to agreements made and to be performed within the State of Delaware, without
giving effect to any choice-of-law provisions thereof that would compel the application of the substantive laws of any other jurisdiction.

4

b.
All legal actions and proceedings arising out of or relating to this Agreement shall be heard and determined exclusively in any
Delaware Chancery Court; provided, that if jurisdiction is not then available in the Delaware Chancery Court, then any
such legal Action may be brought in any federal court located in the State of Delaware or any other Delaware state court. The
parties hereto hereby (x) irrevocably submit to the exclusive jurisdiction of the aforesaid courts for themselves and with respect
to their respective properties for the purpose of any Action arising out of or relating to this Agreement brought by any party
hereto, and (y) agree not to commence any Action relating thereto except in the courts described above in Delaware, other than
with respect to any appellate court thereof and other than Actions in any court of competent jurisdiction to enforce any judgment,
decree or award rendered by any such court in Delaware as described herein. Each of the parties further agrees that notice as
provided herein shall constitute sufficient service of process and the parties further waive any argument that such service is
insufficient. Nothing in this Agreement will affect the right of any party to this Agreement to serve process in any other manner
permitted by Law. Each of the parties irrevocably and unconditionally waives, and agrees not to assert, by way of motion or as
a defense, counterclaim or otherwise, in any Action arising out of or relating to this Agreement or the transactions contemplated
hereby, (i) any claim that it is not personally subject to the jurisdiction of the courts in Delaware as described herein for
any reason, (ii) that it or its property is exempt or immune from jurisdiction of any such court or from any legal process commenced
in such courts (whether through service of notice, attachment prior to judgment, attachment in aid of execution of judgment, execution
of judgment or otherwise) and (iii) that (A) the Action in any such court is brought in an inconvenient forum, (B) the venue of
such Action is improper or (C) this Agreement, or the subject matter hereof, may not be enforced in or by such courts.

c. Each
of the parties hereby waives to the fullest extent permitted by applicable Law any right it may have to a trial by jury with respect
to any litigation directly or indirectly arising out of, under or in connection with this Agreement or the transactions contemplated
hereby. Each of the parties (i) certifies that no representative, agent or attorney of any other party has represented, expressly
or otherwise, that such other party would not, in the event of litigation, seek to enforce that foregoing waiver and (ii) acknowledges
that it and the others hereto have been induced to enter into this Agreement by, among other things, the mutual waivers and certifications
in this Section 12(c).

13.
Assignment; Successors. Neither this Agreement nor any of the rights, interests or obligations hereunder shall be assigned
by any of the parties hereto in whole or in part (whether by operation of Law or otherwise) without the prior written consent
of the other party, and any such assignment without such consent shall be null and void. This Agreement shall be binding upon,
inure to the benefit of and be enforceable by the parties hereto and their respective successors and permitted assigns.

14.
Specific Performance. Each party acknowledges and agrees that the other parties hereto would be irreparably harmed and
would not have any adequate remedy at law in the event that any of the provisions of this Agreement were not performed in accordance
with their specific terms or were otherwise breached. Accordingly, each party agrees that the other parties hereto shall be entitled
to an injunction or injunctions to prevent breaches of this Agreement and to enforce specifically the terms and provisions of
this Agreement, this being in addition to any other remedy to which such parties are entitled at law or in equity.

15.
Severability. In the event that any provision of this Agreement or the application thereof becomes or is declared by a
court of competent jurisdiction to be illegal, void or unenforceable, the remainder of this Agreement will continue in full force
and effect and the application of such provision to other persons or circumstances will be interpreted so as reasonably to effect
the intent of the parties hereto.

16.
Counterparts. This Agreement may be executed in one or more counterparts, all of which shall be considered one and the
same agreement, it being understood that each party need not sign the same counterpart. This Agreement shall become effective
when each party shall have received a counterpart hereof signed by all of the other parties. Signatures delivered electronically
or by facsimile shall be deemed to be original signatures.

17.
Termination. This Agreement shall terminate upon the earliest of (a) the Closing of the Business Combination, (b) the termination
of the BCA in accordance with its terms, and (c) the time this Agreement is terminated upon the mutual written agreement of Ignyte,
the Company and the Sponsor.

[Signature Pages Follow]

5

IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be executed (where applicable, by their respective officers or other authorized persons thereunto duly authorized) as of the date first written above.

	 	IGNYTE:	 
	 	 	 
	 	IGNYE
                                         ACQUISITION CORP.
	 	 	 
	 	By:
                                         	/s/
                                         David Strupp	 
	 	Name:
                                         David Strupp	 
	 	Tile:
                                         Co-Chief Executive Officer
	 	 	 
	 	SPONSOR:	 
	 	 	 
	 	IGNYTE
                                         SPONSOR LLC
	 	 	 
	 	By:
                                         	/s/
                                         David Strupp	 
	 	Name:
                                         David Strupp	 
	 	Tile:
                                         Co-Chief Executive Officer

[Signature Page to Sponsor
Support Agreement]Exhibit 4.16

        

         

        Pursuant to 17 CFR 229.601(b)(10)(iv), confidential information (indicated by [***]) has been omitted from this exhibit because it is both not material and would likely cause competitive harm
            to the registrant if publicly disclosed.

         

        SUPPLY AGREEMENT

         

        (COMMERCIAL PHASE)

         

        This supply Agreement (“Agreement”) is effective as of December 31, 2015 (the “Effective Date”),

          by and between Teva API, Inc., a company duly incorporated under the laws New Jersey, with its principal offices located at 400
          Chestnut Ridge Rd.  Woodcliff, NJ 07677, USA (“TAPI”), and Chiasma, Inc., a company duly
          incorporated under the laws of the State of Delaware, U.S.A., with its principal offices located at 60 Wells Ave.  Suite #102, Newton, MA 02459, U.S.A.  (“Chiasma, Inc.”) on

          its own behalf and on behalf of its Affiliates, as defined below, (collectively, “Chiasma”) (collectively, the “Parties” and each a “Party”).

         

        	Whereas,	
                TAPI through its Affiliates, including Novetide Ltd. of P.O. Box 10140 Haifa 26111, Israel, (“Novetide”) are engaged in the business of manufacturing active pharmaceutical ingredients, drug
                  substances and other pharmaceutical products; and

              

         

        	Whereas,	
                Chiasma is engaged in the business of developing drug delivery technology, and has developed certain products using such drug delivery technology; and

              

         

        	Whereas,	
                Chiasma, Inc. and Novetide have entered into a Manufacturing and Supply Agreement (Clinical Phase) dated December 26, 2012 (the “Clinical Phase Agreement”) for the manufacture and supply by
                  Manufacturer of R&D and registration quantities of API (as defined below), which Clinical Phase Agreement is superseded, canceled and replaced by this Agreement (except for any provisions that survive any termination thereof, as
                  expressly provided therein); and

              

         

        	Whereas,	
                Chiasma desires to engage TAPI hereunder, and TAPI wishes to be so engaged, to have commercial quantities of the API manufactured through any TAPI Affiliate (each and all such Affiliate(s), individually and collectively, the “Manufacturer”) and supply for use by Chiasma for further processing and/or incorporation into Finished Product (as defined below), subject to and in accordance with the terms and conditions of this
                  Agreement; and

              

         

        	Whereas,	
                in order to meet Chiasma’s requirements of API, TAPI has agreed to invest in increasing the manufacturing capacity of the Manufacturing Facility during the Scale-Up Period (as defined below) to support Chiasma’s requirements for API,
                  based on Chiasma’s forecasts in accordance with this Agreement, up to a maximum of [***] per year;

              

         

        Now, Therefore, the Parties hereby agree as follows:

         

        

        
          
            

        

        	1.	
                PREAMBLE, EXHIBITS, DEFINITIONS

              

         

        	1.1	
                the preamble and the exhibits hereto form an integral part of this agreement.

              

         

        	1.2	
                in addition to the various capitalized terms defined elsewhere in this agreement, the following terms shall have the respective meanings ascribed to them below:

              

         

        	

              	1.2.1	
                “API” means the active pharmaceutical ingredient specified in Exhibit A hereto.

              

         

        	

              	1.2.2	
                “Affiliate” means, with respect to any Party, any person or entity who, directly or indirectly
                    controls, is controlled by, or is under common control with, such Party.  A person or entity shall be deemed to control another entity if it owns, directly or indirectly, 50% (fifty percent) or more of the voting shares, or has the
                    power to elect 50% (fifty percent) or more of the directors, of such other entity.

              

         

        	

              	1.2.3	
                “Alternative Material” means Octreotide acetate manufactured by a third party holding a drug
                    master file for such material, the supply of which to Chiasma will not infringe the intellectual property rights of Manufacturer.

              

         

        	

              	1.2.4	
                “Applicable Law” means the applicable laws and regulations, rules and guidelines of any
                    applicable Governmental Authority in a given jurisdiction (whether federal, state, municipal or other) pertaining to the manufacture, packaging, labeling, release, storage, import, export, distribution, marketing, sale and/or intended
                    use of the API.

              

         

        	

              	1.2.5	
                “Approved Subcontractor” shall have the meaning ascribed to such term in Section 2.6 below.

              

         

        	

              	1.2.6	
                “Batch” means a specific quantity of API that is intended to be of uniform character and quality
                    and is produced during the same cycle of manufacture as defined by the applicable Batch Records.

              

         

        	

              	1.2.7	
                “Batch Records” means all of the documentation associated with the manufacture and testing of a
                    given Batch, including production records, sampling documentation, test results, deviation reports, and all applicable manufacture data (including any pertinent output from instrumentation).

              

         

        	

              	1.2.8	
                “Binding Annual Forecast” shall have the meaning ascribed to such term in Section 2.11.2(b)
                    below.

              

         

        	

              	1.2.9	
                “Binding Purchase Order” shall have the meaning ascribed to such term in Section 2.12.3 below.

              

         

        	

              	1.2.10	
                “Business Day” means any day, other than a Friday, Saturday or Sunday, on which commercial banks
                    are generally open for business in Israel and in New York, U.S.A.

              

         

        

        
          
            

        

        
        	

              	1.2.11	
                “CDA” means the Mutual Confidentiality and Non-Disclosure Agreement between Novetide and Chiasma
                    (Israel) Ltd., an Affiliate of Chiasma, Inc.  (which applies also to Chiasma), dated 1 April 2008 and attached hereto as Exhibit B.

              

         

        	

              	1.2.12	
                “Certificate of Analysis” means a document prepared and signed by Manufacturer describing the
                    Specifications of and testing methods applied to the API and performed by Manufacturer or its Approved Subcontractors and the results thereof.  For each Batch of API, Manufacturer shall issue a “Certificate of Analysis”.

              

         

        	

              	1.2.13	
                “Certificate of Compliance” means a document, prepared and signed by Manufacturer, attesting that
                    a particular Batch of API was manufactured in accordance with cGMP, Applicable Law and the Specifications.  The Certificate of Compliance may be included within the Certificate of Analysis, or separately, if required by Chiasma for
                    regulatory purposes or Applicable Law.  The Parties shall from time to time agree upon a format or formats for the Certificate of Compliance to be used under this Agreement.

              

         

        	

              	1.2.14	
                “cGMP” means current good manufacturing practices for pharmaceutical substances or products as
                    set forth by the FDA, the EMA or any of their respective successor agencies, as applicable.

              

         

        	

              	1.2.15	
                “Change Order” means a document mutually approved in writing by both Parties in accordance with
                    the procedures set forth in Section 3.2 below that describes in reasonable detail an amendment or modification to the tasks and Deliverables under this Agreement, and/or to a Binding Purchase Order, and/or additional new tasks,
                    services, deliverables and/or activities to be performed.

              

         

        	

              	1.2.16	
                “Chiasma Property” means all Confidential Information and Intellectual Property of Chiasma
                    provided and/or delivered by or on behalf of Chiasma to Manufacturer for use by Manufacturer solely in connection with the performance of its obligations under this Agreement.

              

         

        	

              	1.2.17	
                “Confidential Information” shall have the meaning ascribed thereto in the NDA.

              

         

        	

              	1.2.18	
                “Deliverables” means the API and other deliverables to be provided and/or delivered by
                    Manufacturer as described in this Agreement (including, in Exhibit A hereto).

              

         

        	

              	1.2.19	
                “Drug Master File” or “DMF” means the drug master file covering the analysis and manufacture of the API, including analytical methods, stability and pharmaceutical data, impurities and manufacturing processes with respect thereto. 
                    The DMF shall comply with the requirements of the competent Regulatory Authorities in each relevant jurisdiction, suitable for supporting drug applications in such jurisdiction.

              

         

        	

              	1.2.20	
                “EMA” means the European Medicines Agency, or any successor agency.

              

         

        

        
          Page 3 of 44

          
            

        

        	

              	1.2.21	
                “FDA” means the United States Food and Drug Administration, or any successor agency.

              

         

        	

              	1.2.22	
                “Finished Product” means the finished commercial dosage form(s) using or incorporating Octreotide
                    acetate, to be marketed and sold by or on behalf of Chiasma and/or its Affiliates and/or licensees.

              

         

        	

              	1.2.23	
                “First Binding [***] Month Forecast” shall have the meaning ascribed to such term in Section
                    2.11.2(a) below.

              

         

        	

              	1.2.24	
                “Force Majeure” means strikes (except of the personnel of the Party claiming Force Majeure),
                    riots, war, act of God, invasion, acts of terrorism, fire, explosion, floods, interruption of or delay in transportation, shortage or failure in the supply of materials, acts of government or governmental agencies or instrumentalities,
                    and any other contingencies beyond the Party’s reasonable control, and without fault of such Party.

              

         

        	

              	1.2.25	
                “Governmental Authority” means any national, state, local, municipal or other government,
                    governmental or quasi-governmental authority of any nature (including any governmental agency, branch, ministry, department, Regulatory Authority, court or other tribunal).

              

         

        	

              	1.2.26	
                “Intellectual Property” means any and all intellectual property including trademarks, service
                    marks, trade dress, logos, copyrights, rights of authorship, inventions, know-how, patents, including all applications and registrations with respect thereto, rights of inventorship, moral rights, trade secrets, industrial design
                    rights, and all other intellectual and industrial property rights related thereto, or otherwise, whether registered, unregistered, statutory, common law, or pending, throughout the world.

              

         

        	

              	1.2.27	
                “Launch” means with respect to each Region, the first commercial sale of Finished Product by or
                    on behalf of Chiasma to an independent third party in any country in such Region; and “Launch Date” means the date of said Launch.

              

         

        	

              	1.2.28	
                “Manufacturing Facility” means the facility in which Manufacturer shall manufacture the API in
                    accordance with the terms of this Agreement, located at Neot Chovav, Israel (currently known as “TevaTech”), and/or Netanya, Israel (currently known as “Plantex”) or any other or additional location pre-approved by Chiasma in writing
                    pursuant to Section 2.5 below.

              

         

        	

              	1.2.29	
                “Manufacturing Process” means the production process and methods for the manufacture of the API,
                    as such process may be changed from time to time in accordance with this Agreement and/or the Quality Agreement.

              

         

        	

              	1.2.30	
                “Marketing Authorizations” means the required permits, authorizations and approvals to be granted
                    by Governmental Authorities in their respective jurisdictions for the marketing, use, sale and/or distribution therein of the Finished Product.

              

         

        

        
          Page 4 of 44

          
            

        

        	

              	1.2.31	
                “Minimum Annual Purchase Requirements” shall have the meaning ascribed thereto in Section 2.1
                    below.

              

         

        	

              	1.2.32	
                “Non-Complying Product” means any Batch of API that does not conform, in whole or in part, with
                    the Drug Master File and the Specifications.

              

         

        	

              	1.2.33	
                “Purchase Orders” shall have the meaning ascribed thereto in Section 2.12.1 below.

              

         

        	

              	1.2.34	
                “Quality Agreement” means the Quality Agreement between Chiasma, Inc. and Novetide and Assia
                    Chemical Industries Ltd. dated December 26, 2012, a copy of which is attached hereto as Exhibit E,
                    containing quality assurance provisions for the manufacture of the API, as may be amended by mutual agreement of the Parties.

              

         

        	

              	1.2.35	
                “Quarter” means any of the traditional fiscal quarters of the calendar year; i.e., each of the three-month periods
                    ending March 31, June 30, September 30 and December 31; and the terms, “Q1”, “Q2”, “Q3” and “Q4” mean the first, second, third and fourth Quarter, respectively, of a given calendar year.

              

         

        	

              	1.2.36	
                “Raw Materials” means the ingredients, solvents and other components required to manufacture the
                    API in accordance with this Agreement.

              

         

        	

              	1.2.37	
                “Region” means each of (i) the U.S.A.; and (ii) the European Economic Area and Switzerland (“EEA”), as applicable, it being agreed that the Region in which the first Launch occurs shall be referred to as the “Lead Region” and the other Region in which a subsequent Launch occurs shall be referred to as the “Other Region”.  Additional regions and/or countries may be added by mutual written agreement of the Parties and subject to the Parties reaching agreement on the commercial and
                    other terms applicable thereto.

              

         

        	

              	1.2.38	
                “Regulatory Authority” means the FDA, EMA or any other federal, state, local or other regulatory
                    agency, authority, or regulatory body having jurisdiction in the relevant Region over TAPI or Manufacturer or its operations, facilities, or performance by TAPI of its obligations hereunder.

              

         

        	

              	1.2.39	
                “Re-Test Period” means a period of [***] years from the date of manufacture of the relevant Batch
                    of API.

              

         

        	

              	1.2.40	
                “Rolling Forecast” shall have the meaning ascribed to such term in Section 2.11.2(a) below.

              

         

        	

              	1.2.41	
                “Scale-Up Period” shall have the meaning ascribed to such term in Section 2.3 below.

              

         

        

        
          Page 5 of 44

          
            

        

        	

              	1.2.42	
                “Shipping Guidelines” means the shipping guidelines and procedures provided by Manufacturer in
                    writing, that describe the methods of packaging, preserving, monitoring and shipping the API to be shipped by Manufacturer, a copy of which is attached to this Agreement as Exhibit F.

              

         

        	

              	1.2.43	
                “Specifications” means the test parameters, test methods, acceptance criteria and requirements of
                    the API as set forth in Exhibit A.

              

         

        	

              	1.2.44	
                “Term” means the term of this Agreement, as defined in Section 7.1 below.

              

         

        	1.3	
                In this Agreement (including the Exhibits hereto), unless the context otherwise requires:

              

         

        	

              	1.3.1	
                “including”, “includes” means including, without limiting the generality of any description preceding such terms;

              

         

        	

              	1.3.2	
                “writing” includes facsimile transmission, electronic transmission, email transmission and
                    comparable means of communication; and

              

         

        	

              	1.3.3	
                any references to the “law” or any provision of a statute shall be construed as a reference to that law or provision as amended, re-enacted, consolidated or extended at the relevant time.

              

         

        	2.	
                PERFORMANCE OBLIGATIONS

              

         

        	2.1	
                Engagement.  Chiasma hereby retains TAPI to have the API manufactured by TAPI through its Manufacturer and
                    to supply the API to Chiasma, directly or through its Affiliates, all subject to and in accordance with the terms and conditions of this Agreement.  TAPI shall have the API manufactured at the Manufacturing Facility and will supply the
                    API to Chiasma, in accordance with orders for API placed by Chiasma from time to time pursuant to this Agreement, for the consideration set out in this Agreement.  Commencing with effect from the Effective Date and thereafter during the
                    Term, and subject to the terms of this Agreement, Chiasma will purchase, at the minimum, the percentage of Chiasma’s total annual requirements of Octreotide acetate, for Chiasma’s consumption in manufacturing of the Finished Product for
                    each Region, as set forth below (the “Minimum Annual Purchase Requirements:

              

         

        	
                Year of Term

              	
                Percentage of API

                Annual

                Requirements

              
	
                Up to end of Year [***] from Launch Date in the Lead Region (the “First Launch Date”)

              	
                [***]%

              
	
                Year [***] from First Launch Date

              	
                [***]%

              
	
                Year [***] from First Launch Date

              	
                [***]%

              
	
                Year [***] from First Launch Date

              	
                [***]%

              
	
                Year [***] from First Launch Date until end of Term*

              	
                [***]%

              

         

        

        
          Page 6 of 44

          
            

        

        	

              	∗	
                only applicable to the Other Region

              

         

        As an illustration, by way of example, the following table sets forth the Minimum Annual Purchase Requirements in the case that the first Launch occurs in the U.S.A. (in which case it will be the
          Lead Region) and [***] years thereafter there is a first Launch in the EEA (the Other Region):

         

        
          	
                  Year of Term

                	
                  Percentage of 

                  API

                  Annual

                  Requirements

                	
                  Active Regions

                
	
                  Year [***] from First Launch Date

                	
                  [***]%

                	
                  [***]

                
	
                  Year [***] from First Launch Date

                	
                  [***]%

                	
                  [***]

                
	
                  Year [***] from First Launch Date

                	
                  [***]%

                	
                  [***]

                
	
                  Year [***] from First Launch Date

                	
                  [***]%

                	
                  [***]

                
	
                  Year [***] from First Launch Date

                	
                  [***]%

                	
                  [***]

                
	
                  Year [***] from First Launch Date

                	
                  [***]%

                	
                  [***]

                

        

         

        Notwithstanding anything in the Agreement to the contrary, as far as terms and conditions of this Agreement apply to a Manufacturer undertaking any activities under this Agreement, TAPI is and
          shall remain responsible for the Manufacturer’s actions and inactions under this Agreement and for its compliance with such applicable terms of this Agreement.

         

        	2.2	
                Manufacturing Facility.  Subject to Sections 2.5 and 2.6 below, the API shall be manufactured by
                    Manufacturer at the Manufacturing Facility, it being agreed, that in addition to the manufacture of API at TevaTech at Neot Chovav, TAPI agrees to take reasonably commercial steps to expedite the commencement of manufacturing of the API
                    at Plantex in Netanya, as a backup manufacturing site.  Manufacturer shall be solely responsible for (i) all scheduling related to the Manufacturing Facility; (ii) the operation of the Manufacturing Facility; and (iii) that the Manufacturing Facility and all equipment used in the Manufacturing Process shall be operated and maintained in such manner and condition as to enable Manufacturer to manufacture the API in compliance with cGMP, Applicable
                    Law and in conformance with the Drug Master File.

              

         

        	2.3	
                Scale Up.

              

         

        	

              	2.3.1	
                TAPI shall use reasonable efforts to ensure the scale up of the Manufacturing Facility at TevaTech at TAPI’s own expense, in order to increase its API output capacity to enable TAPI to meet Chiasma’s
                    requirements in accordance with the Rolling Forecasts provided by Chiasma pursuant to this Agreement, up to a maximum capacity of [***] kg (two hundred kilograms) of API per annum, in lots of approximately [***] kg each but not less
                    than [***]kg each, during a period of [***] commencing on 1 January 2016 (the “Scale Up Period”).

              

         

        

        
          Page 7 of 44

          
            

        

        	

              	2.3.2	
                TAPI shall keep Chiasma reasonably informed and updated on a monthly basis regarding the progress of the said scale up.  Without derogating from the foregoing, the relevant representatives of TAPI and
                  Chiasma shall hold regular meetings (whether by teleconference or in person), at least every [***] weeks or as otherwise requested by Chiasma, to discuss the progress of such scale up and the supply of API during the Scale Up Period and
                  thereafter.

              

         

        	

              	2.3.3	
                If notwithstanding such reasonable efforts by TAPI, TAPI is unable to complete the scale up of the said Manufacturing Facility within the Scale Up Period as stated above, then TAPI shall be entitled
                    to complete such scale up during an additional period of up to [***] months thereafter (the “Buffer Period”).  During the Buffer
                    Period, TAPI shall ensure that API is supplied to Chiasma pursuant to Binding Purchase Orders placed by Chiasma in accordance with the First Rolling Forecast, provided that the quantities of API ordered by Chiasma do not exceed the
                    manufacturing capacity of the said Manufacturing Facility at the relevant time (without the full scale up pursuant to this Section).

              

         

        	

              	2.3.4	
                Without derogating from Section 2.14.2 below, during the Buffer Period and/or prior thereto if it becomes apparent that TAPI will not complete such scale up by the end of the Buffer Period, Chiasma shall be
                  entitled to order Alternative Material (as set forth in Section 2.14.2 below) from any third party to the extent that the quantities of API required by Chiasma exceed the manufacturing capacity of the Manufacturing Facility as aforesaid
                  and/or to the extent of the shortfall in the supply of API by TAPI as provided in Section 2.14.2 below, and the Minimum Annual Purchase Requirements shall be reduced accordingly.  Notwithstanding the foregoing, Chiasma agrees to purchase
                  all quantities of API manufactured by the Manufacturer during the Scale up Period and Buffer Period pursuant to Chiasma’s purchase orders.

              

         

        	

              	2.3.5	
                In the event that TAPI fails to complete such scale up (in lots of at least [***] each) by the end of the Buffer Period, the Minimum Annual Purchase Requirements shall terminate automatically with effect
                  from the date of expiry of the Buffer Period and Chiasma shall be free to order API from TAPI in whatever quantities it decides, in its sole discretion, within the then current manufacturing capacity of the Manufacturing Facility.  The
                  foregoing shall not affect the First Rolling Forecast and Chiasma’s purchase commitment pursuant to Binding Purchase Orders and the Binding Annual Forecast as of the date of termination.

              

         

        	2.4	
                TAPI confirms that the scale up pursuant to Section 2.3 above is designed and planned in a manner that shall enable a subsequent further scale up of the Manufacturing Facility in Tevatech, whereby the API
                  output capacity shall be increased to an annual capacity of [***] of API, in lots of approximately [***] each, which may involve an additional investment by TAPI.  Such subsequent scale up and increase of the API output capacity of the
                  Manufacturing Facility shall be implemented pursuant and subject to terms and conditions to be mutually agreed by the Parties in writing.

              

         

        
          Page 8 of 44

          
            

        

        	2.5	
                Change Of Location Of Manufacturing Facility Or Use Of Additional Facility.

              

         

        TAPI shall not change the location of the Manufacturing Facility or use any additional facility for the manufacture of the API supplied to Chiasma under this Agreement, unless (i) TAPI shall have
          completed all the necessary activities for the operation and validation and approval (if such approval is required by the relevant Regulatory Authorities) of such new location or additional facility (as applicable); (ii) TAPI has provided Chiasma
          at least [***] days prior written notice from the date of completion of the activities referred to in (i) above, in order to enable Chiasma to undertake the necessary activities and procedures for obtaining the required approvals for Finished
          Product manufactured with API from the new location or additional facility, as applicable, and (iii) TAPI shall ensure that during such [***] day period API is manufactured at the current (approved) Manufacturing Facility and delivered to Chiasma
          in accordance with the Purchase Orders placed by Chiasma in accordance with the applicable Binding Annual Forecast.  Prior to the end of such [***] day period, Chiasma shall notify TAPI in writing of any quantities of API to be manufactured at
          the current Manufacturing Facility in excess of the Binding Annual Forecast and which are reasonably required by Chiasma to ensure that there is no interruption in the API supply from TAPI to Chiasma until the necessary approvals of the new
          location or additional facility are obtained by Chiasma.  Chiasma shall be obligated to perform reasonably commercial efforts to obtain such approvals as soon as possible.

         

        TAPI shall co-operate with and assist Chiasma in connection with the said approval process.  Without derogating from the foregoing, TAPI shall facilitate, and co-operate with Chiasma with respect
          to any quality assurance and/or regulatory impact assessment of the new location or additional facility, as the case may be, to be conducted by or on behalf of Chiasma.

         

        	2.6	
                Subcontracting.  Except as specified in the DMF, TAPI shall not subcontract or otherwise delegate any of
                    its obligations under this Agreement to any subcontractor or other third party, without the prior written notification to Chiasma.  TAPI shall ensure that all subcontractors approved by Chiasma as aforesaid (each, an “Approved Subcontractor”):  shall (a) be subject to a written nondisclosure agreement containing terms substantially similar
                    to the terms of the NDA (which may be entered into directly between the Approved Subcontractor and Chiasma, should Chiasma so request); (b) uphold all Applicable Law; and (c) grant Chiasma rights with
                    respect to such Approved Subcontractors that are substantially similar to the access, inspection and audit rights granted to Chiasma under this Agreement, subject to coordination with TAPI.  TAPI shall be responsible for such Approved
                    Subcontractors.

              

         

        	2.7	
                Hazardous Materials.  The generation, collection, storage, handling, transportation, movement and release
                    of hazardous materials and waste (if any) generated in connection with the manufacture of the API shall be the responsibility of Manufacturer.  Without limiting other legally applicable requirements, Manufacturer shall prepare, execute
                    and maintain, as the generator of waste, all licenses, registrations, approvals, authorizations, notices, shipping documents and waste manifests required under Applicable Law.

              

         

        
          Page 9 of 44

          
            

        

        	2.8	
                Health And Safety Procedures.  Manufacturer shall be solely responsible for implementing and maintaining
                    health and safety procedures for the manufacture of the API and for the handling of any materials or waste used in or generated in the manufacture of the API.

              

         

        	2.9	
                Materials And Equipment.

              

         

        	

              	2.9.1	
                Raw Materials Inventory.  Unless the Parties otherwise agree, Manufacturer shall purchase all Raw Materials to be used by
                    Manufacturer in the manufacture of the API, in accordance with the relevant Raw Materials specifications.  Manufacturer shall be responsible for performing all necessary tests, in accordance with the applicable Regulatory Authority’s
                    standards and regulations and Applicable Law, in order to verify that the Raw Materials are suitable and fit for the manufacture of the API in accordance with this Agreement.  Manufacturer shall ensure that at all times throughout the
                    Term, it shall maintain adequate stocks of Raw Materials so as to enable it to fulfill all orders placed by Chiasma in accordance with its forecasting obligations under Section 2.11 below.

              

         

        	

              	2.9.2	
                Protection Of Api, Work In Progress.  Manufacturer shall at all times take such measures as are reasonably required in
                    accordance with industry standards to protect the API and any work in process from risk of loss or damage at all stages of the Manufacturing Process and until delivery to Chiasma pursuant to this Agreement.  TAPI shall ensure that the
                    API is free and clear of any liens or encumbrances.

              

         

        	

              	2.9.3	
                Equipment.  Manufacturer shall have all equipment necessary to manufacture the API under this Agreement and shall maintain
                    such equipment in a state of repair and operating efficiency consistent with the requirements of cGMP and Applicable Law.

              

         

        	2.10	
                Quality Assurance; Quality Control; Regulatory Matters; Audits.

              

         

        	

              	2.10.1	
                Quality Agreement.  Responsibility for quality assurance and quality control of the API shall be governed by the terms of the
                    Quality Agreement.

              

         

        	

              	2.10.2	
                Regulatory Authorities; Assistance.  Chiasma shall be responsible for handling all complaints and communications with
                    Regulatory Authorities with respect to the Finished Product containing API supplied by TAPI pursuant to this Agreement.  TAPI shall provide Chiasma with any assistance required by Chiasma which would be considered appropriate in view of
                    the relevant Regulatory Authority standards in connection with adverse events or effects and complaints relating to the API supplied by TAPI pursuant to this Agreement.

              

         

        

        
          Page 10 of 44

          
            

        

        	

              	2.10.3	
                Permits.  TAPI shall obtain and maintain and/or shall ensure that the Manufacturer obtains and maintains in good order and
                    shall remain in compliance with, at its sole cost and expense, all current regulatory and governmental permits (including health, safety and environmental permits), approvals, licenses and registrations required by Regulatory
                    Authorities for the Manufacturing Facility, the manufacture of the API and in order for it to perform its other obligations hereunder.  TAPI shall promptly provide Chiasma upon its request with copies of the open or accessible parts of
                    the DMF for the API and all changes thereto and a letter of authorization permitting Chiasma to refer to the DMF in applications to applicable Regulatory Authorities and Chiasma shall have the right to use any and all information
                    contained in such parts of the DMF as aforesaid (and any changes thereto, if applicable).

              

         

        	

              	2.10.4	
                Marketing Authorizations.  Chiasma will be responsible for obtaining, at its own expense, all Marketing Authorizations, and
                    Chiasma shall be the sole owner thereof.  TAPI will assist Chiasma in obtaining such approvals and permits by providing documentation and additional data and information to the extent requested and available, without any additional
                    charge to Chiasma.  Without derogating from any obligations of Chiasma under this Agreement (including under Section 13.5 below regarding Chiasma’s sale of all rights and title in and to the Finished Product), Chiasma shall be entitled
                    to sell or otherwise transfer in any manner the Marketing Authorizations directly or indirectly to an entity at its sole discretion.

              

         

        	

              	2.10.5	
                Access Rights.  Chiasma and its licensees (as applicable) shall be permitted to send its or their representatives or agents
                    to inspect the Manufacturing Facility, in accordance with the Quality Agreement, without the need to have additional confidentiality agreements signed by such representative or agents, provided that Chiasma shall ensure such
                    representatives or agents adhere to the confidentiality obligations pursuant to this Agreement, and shall be liable for any breach thereof.  Such inspections shall be limited to [***] per calendar year other than any audits for cause,
                    and [***] participants in each visit.  Manufacturer shall make Manufacturer’s employees and other personnel involved in the performance of Manufacturer’s duties hereunder reasonably available to Chiasma and/or its licensees (as
                    applicable) for such audit purposes.

              

         

        	

              	2.10.6	
                Inspections And Audits By Regulatory Authority.  Manufacturer will permit a Regulatory Authority to perform inspections and
                    audits at the Manufacturing Facility to ensure compliance with cGMP standards and any other Applicable Law.  TAPI will inform Chiasma of the results of any such inspection and provide Chiasma with a copy of any report, document or other
                    written communication received from or provided to such Regulatory Authority, if applicable to the API, or the facilities used to manufacture, test or warehouse the API supplied to Chiasma.  In the event that any Regulatory Authority
                    shall determine, as a result of an audit or inspection, that Manufacturer is not in compliance with cGMP and/or any Applicable Law with respect to the manufacture of the API, Manufacturer shall, at its expense, use its best efforts to
                    cure such non-compliance promptly.  In the event that Manufacturer is unable to manufacture and supply API as aforesaid for a period of [***] days due to the action of a Regulatory Authority, then, without limiting any rights or
                    remedies to which Chiasma may be entitled under this Agreement or by Applicable Law, Chiasma may terminate any pending Purchase Orders under this Agreement immediately upon written notice to TAPI.  During the first such [***] days of
                    inability to manufacture and supply API, the provisions of section 2.14 will apply, mutatis mutandis.

              

         

        

        
          Page 11 of 44

          
            

        

        	2.11	
                Forecasts

              

         

        	

              	2.11.1	
                [***]-Year Forecast.  A non-binding forecast of Chiasma’s API
                    requirements over the first [***] years from 1 January 2016 in the Lead Region is specified in Exhibit G attached hereto (the
                    “Long Term Forecast”).

              

         

        	

              	2.11.2	
                Rolling Forecasts.

              

         

        	

              	(a)	
                The first [***] months (specified on a quarterly basis) of the Long Term Forecast shall be the “First Rolling Forecast”, the first [***] months of which shall be binding on the Parties (such first
                  [***]-month binding forecast, the “First Binding [***] Month Forecast”).  The last [***] months of the First Rolling Forecast are not binding.  By the end of March 2016 and during the last month of each calendar quarter thereafter
                  throughout the Term, Chiasma shall provide TAPI with a [***] month rolling forecast (on a Quarterly basis) of its API requirements for the [***] months period starting at the beginning of the Quarter following the Quarter in which the
                  forecast is provided (each, a “Rolling Forecast”).  For example, the second Rolling Forecast specifying Chiasma’s API requirements for the [***] months period starting 1 April 2016 will be provided in March of 2016 and so forth.  In no
                  event shall a Rolling Forecast require the manufacture of and/or delivery of API by TAPI in excess of the Quarterly quantity of [***], Should Chiasma require more than [***]kg of API in a calendar quarter, the Parties shall discuss in
                  good faith the required measures to be taken.

              

         

        Within [***] business days of receipt of each Rolling Forecast (other than the First Rolling Forecast), TAPI shall provide Chiasma with written confirmation of receipt of
          such Rolling Forecast and TAPI shall notify Chiasma in writing of its acceptance or rejection of such Rolling Forecast no later than [***] days of receipt thereof.  In the case of a rejection, TAPI’s notice of rejection shall be accompanied by a
          proposal by TAPI with respect to changes to such Rolling Forecast which would be acceptable to TAPI and the Parties shall endeavor, in good faith, to reach agreement with respect thereto.  The failure by TAPI to respond to such Rolling Forecast
          as stated above (i.e. acceptance or rejection) shall be deemed acceptance thereof by TAPI, provided that TAPI shall have notified Chiasma of receipt of the Rolling Forecast as aforesaid.

         

        

        
          Page 12 of 44

          
            

        

        	

              	(b)	
                The first [***] months covered by each Rolling Forecast (provided that the First Binding [***] Month Forecast shall remain binding) shall be binding on the Parties (each, a “Binding Annual Forecast”).  The last [***] months of each Rolling Forecast are non-binding, provided, however, that the quantities in months [***]
                    of a Rolling Forecast shall not deviate (whether increase or decrease) by more than [***] in the applicable period of the following Rolling Forecasts.  For example (the numbers in red represent allowed changes):

              

         

        [***]

         

        	2.12	
                Orders.

              

         

        	

              	2.12.1	
                Chiasma shall be obligated to place firm purchase orders (“Purchase Orders”) for the quantities
                    of API set forth in the First Binding [***] Month Forecast and all subsequent Binding Annual Forecasts, as applicable, provided to TAPI.  Purchase Orders shall reference this Agreement and specify the API, quantities, prices, delivery
                    destination and required delivery dates, which shall in each case be at least [***] days from the date of placing the Purchase Order, except as otherwise specifically and expressly agreed to in writing by TAPI (“Lead Time”).  Deviations (whether
                    increases or decreases) of up to [***] shall be permitted between the quantities of API set forth in any particular Quarter of the Binding Annual Forecast (excluding the first Quarter of any Rolling Forecast submitted) and the
                    quantities set forth in the Purchase Order applicable to such quarter (“Permitted Variations”).  No deviations shall be permitted
                    after submission of the Purchase Orders.

              

         

        	

              	2.12.2	
                Purchase Orders shall be subject to confirmation and acceptance by TAPI, to be provided in writing within [***] business days after the receipt by TAPI of such Purchase Order.  TAPI shall be obligated
                    to accept all Purchase Orders for quantities of API which are in accordance with the quantities set forth in the First Binding [***] Month Forecast and the relevant Binding Annual Forecast and the Permitted Variations (which, for
                    clarification do not apply to the First Binding [***] Month Forecast), as applicable.  Rejection by TAPI of such Purchase Orders without providing an alternative schedule of supply acceptable to Chiasma shall be considered to be Supply
                    Failure (as defined in Section 2.14.2 below) and the provisions of Section 2.14 below shall apply mutatis mutandis.  Without
                    derogating from the foregoing, TAPI shall use commercially reasonable efforts to accept and fulfill Purchase Orders for quantities of API which exceed the quantities set forth in the in the First Binding [***] Month Forecast and Binding
                    Annual Forecast and the Permitted Variations, as applicable, provided such additional supply shall not affect TAPI’s ability to fulfill subsequent supplies according to the Rolling Forecasts.

              

         

        

        
          Page 13 of 44

          
            

        

        	

              	2.12.3	
                TAPI shall supply the quantities set forth in every Purchase Order placed by Chiasma pursuant to this Agreement that has been accepted (“Binding

                    Purchase Order”), within the specified delivery date (subject to the Lead Time) set forth therein.

              

         

        	2.13	
                Delivery, title and risk of loss.

              

         

        TAPI shall deliver the API to Chiasma or its designee(s), in accordance with the Binding Purchase Orders placed by Chiasma, the Shipping Guidelines and Applicable Law.  All API shall be packaged
          and stored in such a manner as to ensure that such API is maintained at specified environmental conditions in accordance with the Specifications.  Each delivery of API shall be made DAP (Incoterms® 2010) the location designated by Chiasma in US,
          Israel or EU, unless otherwise agreed by the Parties in writing.  Chiasma shall receive title to the API, and the risk of loss shall pass to Chiasma at the time of delivery of the API in accordance with the DAP (Incoterms ® 2010) terms.  In the
          event that Chiasma orders quantities of less than [***] of API per shipment, such shipment will incur an additional shipping cost of $[***].

         

        	2.14	
                Delays; Failure To Perform.

              

         

        	

              	2.14.1	
                TAPI shall promptly inform Chiasma in writing if it has reason to believe that it will be unable to deliver any API ordered by Chiasma hereunder (in whole or in part) by the confirmed delivery date or any
                  other Deliverables, and/or of any delay in meeting the confirmed delivery dates by more than [***] days (as the case may be) together with an estimate of actual delivery dates of the particular Deliverables.  In the event of TAPI’s
                  inability to deliver at least [***]% of the API ordered by Chiasma under Binding Purchase Orders or a delay in delivering any API or other Deliverables under Binding Purchase Orders by more than [***] days (including due to Force
                  Majeure), the Parties shall determine a reasonable course of action, including revised timelines, to be taken by TAPI to rectify the matter as soon as possible.  Notwithstanding the above, TAPI shall use reasonable efforts to make up as
                  soon as possible for any shortfall (of more than [***]%) of the ordered quantity under a Binding Purchase Order.

              

         

        	

              	2.14.2	
                Should TAPI fail to remedy such inability or delay within such revised timelines, then, to the extent of TAPI’s shortfall, and unless such inability or delay either is excused by Force Majeure
                    pursuant to Section 12 below, or has been caused solely by Chiasma (such uncured inability to supply or delay by TAPI as aforesaid, a “Supply Failure”):  (a) Chiasma shall be entitled,
                    at its sole discretion, to cancel the applicable Binding Purchase Order(s) for API placed by it hereunder with respect to the quantities that TAPI could not deliver; and (b) for so long as TAPI’s inability persists, Chiasma shall be entitled, notwithstanding the provisions of Section 2.1 above, to purchase Alternative Material, for the quantities
                    that TAPI could not deliver from any third party, until such time as TAPI is able to resume supply of the API, which shall be notified by TAPI to Chiasma in writing.  The foregoing shall not affect any orders for API placed by Chiasma
                    with any such third party, which have not as yet been delivered prior to receipt by Chiasma of such written notification by TAPI.

              

         

        

        
          Page 14 of 44

          
            

        

        	

              	2.14.3	
                Any quantities of Alternative Material purchased by Chiasma pursuant to this Section 2.14 above (including all orders for API placed by Chiasma as referred to in 2.14.2 above) shall be deemed to have been
                  purchased from TAPI for the purpose of determining compliance by Chiasma with its Annual Binding Forecasts or, with the First Binding [***] Month Forecast- if occurring during the Scale Up Period.

              

         

        	

              	2.14.4	
                If in any calendar year during the Term, TAPI has not fulfilled 100% of the ordered quantities under the Binding Purchase Order issued in that calendar year, then, Chiasma shall be entitled, notwithstanding
                  the provisions of Section 2.1 above, to purchase from any third party Alternative Material, for such quantities that TAPI could not deliver and such quantities shall, in addition to and without limiting from Section 2.14.3 above, be
                  deemed to have been purchased from TAPI for the purpose of determining compliance by Chiasma with its Annual Binding Forecasts for that same calendar year.

              

         

        	

              	2.14.5	
                In the event that a Supply Failure occurs on [***] occasions in any period of [***] starting from 1 April 2018, in each case as a result of a different root causes, then, without derogating from the
                  provisions of Section 2.14.2 above, the Minimum Annual Purchase Requirements shall be reduced by [***] for the remainder of the Term of this Agreement.

              

         

        	

              	2.14.6	
                Without derogating from the foregoing, in the event that a Supply Failure occurs on [***] (occasions) starting from 1 April 2018 in any period of [***], in each case as a result of a different root causes,
                  then such Supply Failure shall constitute a material breach of this Agreement, Chiasma shall be entitled to terminate this Agreement in accordance with Section 7.2 below.

              

         

        	2.15	
                Acceptance Of Shipments; Non-Conformance.

              

         

        	

              	2.15.1	
                Unless otherwise instructed by Chiasma in writing, TAPI will in all cases provide to Chiasma a Certificate of Analysis, Certificate of Compliance (if not included within the Certificate of Analysis), and
                  all other documents reasonably required for effecting the shipment on or before the delivery time for each Batch of API ordered hereunder.

              

         

        

        
          Page 15 of 44

          
            

        

        	

              	2.15.2	
                Within [***] days following actual receipt of any Batch of API by or on behalf of Chiasma, at the location nominated by Chiasma, Chiasma shall visually inspect or have visually inspected each Batch of API
                  for damage, defects or shortage, and shall have the right to give TAPI notice of rejection of any Non-Complying Product according to such visual inspection.  Chiasma may also, at any time within [***] days following actual receipt of any
                  Batch of API by or on behalf of Chiasma, give TAPI notice of rejection of any Non-Complying Product according to any further analysis or inspection for conformance with Specifications performed on samples of the API by or on behalf of
                  Chiasma.

              

         

        	

              	2.15.3	
                Upon receipt of any notice of rejection from Chiasma as aforesaid, TAPI shall conduct an internal investigation.  Failure by Chiasma to give notice of rejection within the timelines set forth in
                    Section 2.15.2 above shall constitute acceptance by it of the shipment to which the notice of rejection would have otherwise applied, except in the event of latent defects which are not detectable by means of either of the above
                    inspections, which render the API not conforming as provided herein (“Latent Defects”), which shall be notified to TAPI within a
                    reasonable time after Chiasma becomes aware that such API is a Non-Complying Product, but in no event later than the end of Retest Period of the API.

              

         

        	

              	2.15.4	
                In the event of any disagreement between TAPI and Chiasma as to whether any API is a Non-Complying Product, the Parties shall use good faith efforts to reach an amicable resolution of such
                    disagreement.  In the event that a resolution cannot be reached, and upon the request of either Party, an independent third party laboratory or expert with expertise and experience in the relevant field (the “Expert”) shall be appointed by the Parties to resolve the disagreement.  The Expert shall act as an expert and not as an arbitrator.  The Parties
                    shall assist each other and provide all reasonably required information and execute documents reasonably required by such Expert to enable it to determine whether the API is conforming.  The decision of the Expert shall be binding on
                    the Parties and non-appealable, and the costs of such Expert shall be borne by the Party hereunder determined by the Expert to be the non-prevailing Party in such disagreement.

              

         

        	

              	2.15.5	
                Any API determined to be a Non-Complying Product pursuant to this Section 2.15 above shall be returned by Chiasma to TAPI or discarded (at TAPI’s election), at TAPI’s expense, and shall be replaced by TAPI
                  and delivered to the facility of Chiasma or its designee at no extra charge to Chiasma.

              

         

        	

              	2.15.6	
                In the event TAPI cannot replace such returned API, it shall refund to Chiasma the amount paid therefor.  TAPI will not be entitled to any fees or costs for any API determined to be a Non-Complying Product
                  in accordance with this Section 2.15, it being agreed that Chiasma shall only be obligated to make payment for replacement API that is conforming under this Agreement.

              

         

        	

              	2.15.7	
                Moreover, in the event that any API is a Non-Complying Product, the Parties shall meet to discuss, evaluate and analyze the reasons for and implications of any failure by TAPI to deliver conforming API and
                  shall decide upon an appropriate course of action.  Without derogating from the aforegoing, Chiasma may at any time prior to the Expert’s decision, request that TAPI provide it with API in place of the Non-Complying Product.  TAPI shall
                  fulfill such request for the replacement API as soon as practicable, subject to Chiasma issuing an applicable Purchase Order for such replacement.

              

         

        

        
          Page 16 of 44

          
            

        

        	

              	2.15.8	
                In the event that TAPI delivers Non-Complying Products (excluding if such Non-Complying Products is a result of Latent Defects) on [***] occasions in any period of [***], in each case as a result of a
                  different root cause, such delivery of Non-Complying Products shall constitute a material breach of this Agreement by TAPI and Chiasma shall be entitled to terminate this Agreement in accordance with Section 7.2 below.

              

         

        	

              	2.15.9	
                Without derogating from Chiasma’s rights pursuant to Section 2.14.2 and Section 2.15.8 above, TAPI’s obligation to replace Non-Complying Products, shall be Chiasma’s sole remedies for Non-Complying
                  Products.

              

         

        	2.16	
                Recalls.

              

         

        In the event Chiasma shall be required to recall any Finished Product because such Finished Product may violate Applicable Law or the applicable specifications (including the Specifications), or
          in the event that Chiasma elects to institute a voluntary recall, Chiasma shall be responsible for coordinating such recall.  Chiasma promptly shall notify TAPI if any Finished Product is the subject of a recall and provide TAPI with a copy of
          all documents relating to such recall.  TAPI shall cooperate with Chiasma in connection with any recall and Chiasma shall be responsible for all of the costs and expenses of such recall.

         

        	2.17	
                Delay or failure to obtain marketing authorization.

              

         

        In the event that Chiasma does not obtain a Marketing Authorization from the FDA by 30 April 2016, Chiasma shall promptly notify TAPI thereof in writing.  Within [***] days after such
          notification, Chiasma shall be entitled, in its sole discretion, by written notice to TAPI (the “Suspension Notice”), to require the suspension of all obligations of the Parties under this Agreement with
          respect to the purchase, manufacture and supply (as applicable) of API (including TAPI’s obligations under Section 2.3 herein) until written notification by Chiasma to TAPI that it has received Marketing Authorization from the FDA or the EMA (the
          “Marketing Authorization Approval Notice”).  In such event of providing a Suspension Notice, the following shall apply:

         

        	

              	2.17.1	
                subject to Section 2.17.2 below, with effect from the date of delivery of the Suspension Notice to TAPI as aforesaid (the “Suspension Date”) (i) the First Rolling Forecast (including, the First Binding [***] Month Forecast) shall be cancelled; and (ii) all purchase and supply obligations of the Parties (including the Minimum Annual Purchase
                    Requirements and all obligations of Chiasma to deliver Rolling Forecasts) shall be suspended until delivery to TAPI of the Marketing Authorization Approval Notice;

              

        
          Page 17 of 44

          
            

        

        	

              	2.17.2	
                all pending Binding Purchase Orders as of the date of the Suspension Notice, including the Purchase Orders attached hereto as Exhibit H, shall remain binding on the Parties;

              

         

        	

              	2.17.3	
                Chiasma shall make payment to TAPI as follows:

              

         

        	

              	(a)	
                Chiasma shall pay TAPI for the API supplied by TAPI to Chiasma pursuant to the Purchase Orders specified in Section 2.17.2 above in accordance with Section 4 below at the price that would have been
                  applicable had the Marketing Authorization been granted by the FDA by 30 April 2016;

              

         

        	

              	(b)	
                within [***] days from the Suspension Date, Chiasma shall pay TAPI a one-time payment in an amount equal to US$ [***], as consideration for the services and costs incurred by TAPI.

              

         

        	

              	(c)	
                Subject to payment by Chiasma to TAPI pursuant to Subsections 2.17.3 (a) and (b) above, and in the event that Chiasma shall provide TAPI a Marketing Authorization Approval Notice, then Chiasma shall resume
                  purchase of the API from TAPI and the prices for future quantities of the API purchased by Chiasma shall be the prices set forth in Exhibit C under the column titled “Discounted API Price”.  The Discounted API Price will apply for all
                  quantities of API ordered by Chiasma until the total discount value (calculated by subtracting the amount that would have been paid by Chiasma per the “API Price Post Scale Up Period”, as provided in Exhibit C and the amount paid by
                  Chiasma per the “Discounted API Price”) will equal an amount of US$ [***].  Thereafter, the API price will be the price set forth in Exhibit C under the column titled “API Price Post Scale Up Period”.

              

         

        The above payments by Chiasma shall be made against a valid tax invoice from TAPI.  Such payments by Chiasma shall constitute TAPI’s sole remedy in the event that Chiasma does not obtain a
          Marketing Authorization from the FDA and Chiasma exercises its rights under this Section 2.17 above.

         

        	2.18	
                API Resale

              

         

        Chaisma and its Affiliates are prohibited from reselling or otherwise transferring all or any portion of API that is not used in the manufacture of Finished Products to any other person or
          entity, either directly or indirectly, including through its contract manufacturers or other third parties, without prior written permission of TAPI.

         

        	2.19	
                Chiasma’s Reporting Requirements

              

         

        No later than [***] days from the end of each calendar year, Chiasma will provide TAPI a report of its annual consumption in manufacturing of the Finished Product for each Region for the previous
          calendar year, the Minimum Annual Purchase Requirements for that year and the quantities ordered from TAPI for that year

         

        

        
          Page 18 of 44

          
            

        

        	3.	
                RETENTION OF SAMPLES; CHANGE ORDER

              

         

        	3.1	
                Retention of Samples.  TAPI shall
                    submit samples of API to Chiasma in accordance with Exhibit D hereto, upon Chiasma’s written request, at no additional cost to Chiasma, except as otherwise provided in Exhibit D.

              

         

        	3.2	
                Change Order.  If Chiasma wishes to change the scope of a Binding Purchase Order prior to its delivery, or
                    to have TAPI modify the Specifications or perform other tasks or activities not initially covered by this Agreement, Chiasma shall notify TAPI to such effect and TAPI shall submit to Chiasma a written cost estimate (including, in the
                    case of a reduction in scope - for Raw Materials already used) or a new delivery timeline (including, in the case of an increase of scope).  No such request shall be binding unless and until it has been agreed to in a Change Order
                    signed by both Chiasma and TAPI.  In addition, any modifications required by any Regulatory Authority and/or requested by TAPI shall be made in accordance with the above procedure, subject to Chiasma’s agreement as to such
                    modifications, including the timelines and terms under which such modifications shall be implemented, which agreement shall not be withheld unreasonably.  Without derogating from any right or remedy to which Chiasma may be entitled, if
                    any such modifications, additional services, deliverables, tasks, activities or repeat work are required due to Manufacturer’s fault, negligence or breach of its obligations hereunder, TAPI shall promptly perform same in accordance with
                    the terms of this Agreement and subject to Chiasma’s prior written consent, at TAPI’s full cost, risk and expense.

              

         

        	4.	
                CONSIDERATION; PAYMENT; TAPI AUDIT RIGHTS

              

         

        	4.1	
                Fees and Costs.

              

         

        In consideration for delivery of the API and the other Deliverables provided by TAPI hereunder, Chiasma shall pay TAPI the fees and prices set forth in the Exhibit C attached hereto.  All amounts payable to TAPI as aforesaid are inclusive of all taxes, excluding value added tax (if applicable).

         

        The consideration as set forth herein constitutes the only consideration payable to TAPI by Chiasma for performance by TAPI of its obligations under this Agreement, and Chiasma shall not be
          liable for any additional payments without Chiasma’s prior written consent thereto.

         

        

        
          Page 19 of 44

          
            

        

        	4.2	
                Invoices; Payment.

              

         

        TAPI shall provide Chiasma with a detailed invoice in accordance with each Binding Purchase Order, which invoice shall set forth the API delivered.  Except as otherwise provided in this Agreement
          and unless otherwise agreed by the Parties in writing, each TAPI invoice shall be payable within [***] days after the end of the month in which the invoice is received by Chiasma.  The fees and charges due hereunder shall be payable in U.S.
          Dollars unless otherwise agreed by Parties.  All payments due from Chiasma hereunder shall be paid by wire transfer to TAPI’s bank account, the details of which are notified to Chiasma.  Should Chiasma notify TAPI that it disputes or challenges
          any or all amounts in an invoice, the Parties shall enter into discussions in good faith in order to reach an amicable resolution of the dispute.  Any disputes that cannot be resolved amicably shall be resolved in accordance with the provisions
          of Section 10 below.  Amounts not paid after a grace period of [***] days from due date of payment shall accrue interest calculated from the due date of payment until the date of actual payment thereof at the rate of [***] plus the U.S. prime
          rate (but in no event greater than the maximum rate permitted by law) in effect on the date that the payment should have been made, as published in The Wall Street Journal, Eastern U.S. Edition, calculated on a daily basis.  Subject to Section
          13.4, no deductions of any kind from any payment becoming due to TAPI may be made in the absence of an official credit memorandum from TAPI authorizing the deduction.

         

        	4.3	
                TAPI Audit Rights

              

         

        Chiasma shall keep full and true books of account and other records in accordance with generally accepted accounting principles in the Region so that details of Chiasma’s total annual
          requirements of Octreotide acetate may be properly ascertained.

         

        Chiasma agrees, on not less than a [***] day written notice from TAPI and not more than once in each calendar year during the term of this Agreement, to permit an independent certified public
          accounting firm or other financial industry expert selected by TAPI, at TAPI’s expense to have access, at a time convenient to Chiasma, to such books of account and other pertinent records as may be reasonably necessary to verify compliance of
          Chiasma’s Minimum Annual Purchase Requirements pursuant to this Agreement.  Such records shall include, but not be limited to Chiasma’s total purchases from all sources of API for the manufacture of the Finished Product during the reviewed
          period.  This right shall survive termination of this Agreement for [***] years.  The accounting firm shall disclose to TAPI only whether the Minimum Annual Purchase Requirements have been met, and if not met, the amount of any discrepancy.  In
          the event that a discrepancy of more than [***] will be ascertained by the auditing firm, Chiasma shall bear the costs of the audit, shall immediately place Orders for the shortfall quantities, and the Price of such quantities shall be the price
          of the API as invoiced in the applicable year + [***].  No other information shall be provided to TAPI.  TAPI shall treat all information subject to review under this Section 4.3 in accordance with the confidentiality and non-use provisions of
          this Agreement, and shall cause its accounting firm to enter into an acceptable confidentiality agreement with Chiasma obligating it to retain all such information in confidence pursuant to such confidentiality agreement. 

         

        	5.	
                OWNERSHIP OF INTELLECTUAL PROPERTY AND PROPRIETARY RIGHTS

              

         

        	5.1	
                Pre-Existing IP.  Each Party shall continue to own or to retain the rights in the Intellectual Property
                    and Confidential Information owned or licensed by such Party prior to and as of the Effective Date, or acquired by such Party or developed by such Party independently of this Agreement during the Term.

              

         

        
          Page 20 of 44

          
            

        

        	5.2	
                Ownership by Chiasma - Chiasma Inventions; License to Manufacturer.

              

         

        Without derogating from Section 5.1 above, the Parties agree that all inventions, discoveries, designs, procedures, methods, processes, know-how, and any improvements relating thereto, whether
          patentable or not, (collectively, “Inventions”):  (i) relating directly to Confidential Information or Intellectual Property of Chiasma, which
          are made, developed, or discovered by or on behalf of TAPI and/or the Manufacturer (including, by any Approved Sub-contractor), as a result of the performance of its obligations under this Agreement, and/or (ii) that TAPI and/or the Manufacturer (including, by any Approved Sub-contractor) was specifically required by Chiasma to design or develop for Chiasma under a separate
          agreement (collectively, “Chiasma Inventions”); and all related Intellectual Property, shall be and remain the exclusive property of Chiasma and all works of authorship, if applicable, shall be deemed
          “works-made-for-hire”.

         

        TAPI shall promptly disclose in writing to Chiasma any Chiasma Inventions.  TAPI shall assign and shall cause its Affiliates, employees, subcontractors, agents or anyone acting on its behalf to
          assign any and all right, title and interest in any Chiasma Inventions and related Intellectual Property to Chiasma, at no cost to Chiasma, including by executing any documents or instruments that may be required by Chiasma.

         

        Chiasma shall be free to use any Chiasma Invention and related Intellectual Property as it sees fit.

         

        Chiasma hereby grants to Manufacturer during the term of this Agreement, a fully paid, non-exclusive, limited license to use any and all Chiasma Inventions owned by Chiasma as aforesaid, to the
          extent necessary and solely for the limited purpose of enabling Manufacturer to perform its obligations under this Agreement.  All Chiasma Inventions owned by Chiasma as aforesaid shall be deemed to be Confidential Information of Chiasma for the
          purposes of this Agreement and the NDA.

         

        	5.3	
                Ownership by Manufacturer — Records, Inventions; License to Chiasma.

              

         

        All Records developed or generated by or on behalf of Manufacturer in the performance of this Agreement shall be and remain the exclusive property of Manufacturer.

         

        Without derogating from Section 5.1 above, the Parties agree that any Inventions (other than Chiasma Inventions) (i) made, developed or discovered solely by or on behalf of Manufacturer
          (including, by an Approved Subcontractor) that relate to Manufacturer’s activities and/or its products (including the API), formulation, analysis and/or the manufacturing process of active pharmaceutical ingredients (including the Manufacturing
          Process), or (ii) relating directly to Confidential Information or Intellectual Property of Manufacturer, which are made, developed, or discovered by or on behalf of Chiasma (collectively, “Manufacturer Inventions”)

          and all related Intellectual Property, shall be and remain the exclusive property of Manufacturer.  All Manufacturer Inventions shall be deemed to be Confidential Information of Manufacturer for the purposes of this Agreement and the NDA.

         

        

        
          Page 21 of 44

          
            

        

        Chiasma shall promptly disclose in writing to TAPI any Manufacturer Inventions created under (ii) above.  Chiasma shall assign and shall cause its employees, subcontractors, agents or anyone
          acting on its behalf to assign any and all right, title and interest in any such Manufacturer Inventions and related Intellectual Property to Manufacturer, at no cost to Manufacturer, including by executing any documents or instruments that may
          be required by Manufacturer.

         

        Each of TAPI and Manufacturer hereby grants to Chiasma, a non-exclusive, perpetual, irrevocable, worldwide, royalty-free, fully paid-up, sublicensable license to use any and all such Records and
          Manufacturer Inventions owned by TAPI and/or Manufacturer as aforesaid, solely in connection with the use by Chiasma of the API supplied to Chiasma under this Agreement and/or the development, manufacture, use, marketing, sale, and distribution
          of the Finished Product.

         

        	5.4	
                No Other Licenses.  Except as otherwise expressly provided in this Agreement, nothing contained in this
                    Agreement shall be construed as:  (i) granting Manufacturer any ownership, license or other rights, express or
                    implied, in or to any Confidential Information and Intellectual Property of Chiasma and/or any Chiasma Inventions; or (ii) granting Chiasma any ownership, license or other rights, express or implied, in or to any Confidential Information and Intellectual Property of Manufacturer and/or
                    any Manufacturer Inventions.

              

         

        	6.	
                CONFIDENTIALITY

              

         

        The Parties agree that any confidential and/or proprietary information of a Party or its Affiliates disclosed to the other Party or its Affiliates and/or their employees hereunder in any form,
          whether oral, written or otherwise, and the terms and conditions of this Agreement will be deemed to be “Confidential Information” for the purpose of the CDA and the terms and conditions of the CDA shall apply thereto as if the relevant
          disclosing party and receiving party have been an original parties of the CDA, provided that in the case of any oral disclosures, a written summary thereof is provided to the receiving Party within [***] days of such disclosure.  For the
          avoidance of doubt, the terms and conditions of the CDA shall continue to be of full force and effect during the term of and shall survive the termination of this Agreement for any reason for a period of [***] years.

         

        Without derogating from the provisions of the CDA, it is agreed that either Party shall be entitled to disclose Confidential Information of the other Party for the purposes of obtaining approvals
          from any Regulatory Authority as contemplated in this Agreement subject to the provision of prior notice to the other Party, in the fulfillment of the requirements of applicable securities laws and/or any stock exchange, for the implementation of
          this Agreement and/or the exercise of any rights or obligations of such Party hereunder, subject to the provisions of the CDA.  In addition, Chiasma shall be entitled to disclose the terms of this Agreement to potential investors, acquirers,
          licensees and/or collaborators under appropriate non-disclosure agreements.

         

        

        
          Page 22 of 44

          
            

        

        	7.	
                TERM; TERMINATION

              

         

        	7.1	
                Term.  This Agreement shall enter into effect on the Effective Date and shall continue with respect to
                    each Region, respectively, until the [***] anniversary of the first Launch Date in such Region (the “Region Term”), and shall expire
                    and have no further force or effect upon the expiry of the last Region Term, unless terminated earlier pursuant to this Section 7 below (the “Term”).

              

         

        	7.2	
                Termination by Chiasma.

              

         

        In the event that a Supply Failure occurs as provided in Section 2.14.5 above or TAPI delivers Non-Complying Products as provided in Section 2.15.8 above, respectively, then Chiasma shall be
          entitled to terminate this Agreement by providing [***] days prior written notice to TAPI.

         

        	7.3	
                Termination by Either Party; Termination by Manufacturer.

              

         

        Termination by either Party for Cause.  Either Party may terminate this Agreement by serving a written notice to that effect on the other Party:  (i) in accordance with Section 12 below; (ii) if the other Party commits a material
          breach of this Agreement, and such breach is not cured within [***] days after receipt by the breaching Party of a written notice from the non-breaching Party in respect of such breach, or such additional time reasonably necessary to cure such
          breach, which in no event shall be more than [***] days after receipt by the breaching Party of written notice of breach, provided that the breaching Party can demonstrate that it is making commercially reasonable efforts to cure such breach; or
          (iii) if a Party shall become bankrupt or insolvent, or file a petition for winding-up or liquidation or for the appointment of a receiver over
          its assets, or a substantial part thereof, or shall make an assignment for the benefit of creditors, provided that such petition or appointment shall not be withdrawn, dismissed or vacated, as the case may be, within [***] days after the filing
          or appointment, if applicable.

         

        	7.4	
                Payment Upon Termination.

              

         

        Upon termination of this Agreement in accordance with Section 7.2 or 7.3 above, Chiasma shall pay TAPI any outstanding undisputed fees and charges for the API and other Deliverables delivered in
          accordance with this Agreement, until the effective date of termination, against an invoice provided to Chiasma in accordance with Section 4.2 above, or as otherwise agreed to in writing by the Parties, and shall pay TAPI for all Purchase Orders
          placed by Chiasma in accordance with the relevant Binding Annual Forecast for the period of [***] months following the effective date of termination and supplied by TAPI pursuant to Section 7.5 below, against an invoice provided to Chiasma in
          accordance with Section 4.2 above.

         

        

        
          Page 23 of 44

          
            

        

        	7.5	
                Tapi’s Duties Upon Termination.

              

         

        TAPI shall, upon receipt of a termination notice from Chiasma pursuant to this Section 7, promptly cease performance of its obligations under this Agreement, except as expressly provided in this
          Section 7.5 below.

         

        TAPI shall complete the preparation of any Batch that is in the process of being prepared or runs in process and manufacture and supply API to Chiasma pursuant to all Purchase Orders placed by
          Chiasma in accordance with the relevant Binding Annual Forecast for the period of [***] months following the effective date of termination, in which event the Agreement shall continue in full force and effect with respect to such Purchase Orders.

         

        	7.6	
                Return of Materials; Confidential Information.  Upon termination of this Agreement, and subject to any
                    obligations of Manufacturer to retain any documents pursuant to this Agreement, and following a Party’s written request, the other Party shall promptly deliver to the requesting Party all Confidential Information of the requesting
                    Party, and all copies or other manifestations thereof, regardless of the method of storage or retrieval, or, at requesting Party’s election, shall destroy any of the aforegoing as instructed in writing, and shall provide requesting
                    Party with written certification of its compliance with such instructions, at requesting Party’s cost.

              

         

        	7.7	
                Termination of Licenses.  Except where otherwise necessary pursuant to Section 7.5 above, all licenses
                    granted hereunder shall immediately terminate and be of no further force and effect upon termination of this Agreement for any reason.

              

         

        	7.8	
                Survival.  The termination of this
                    Agreement for any reason shall not relieve a Party of any of its respective obligations which shall have accrued prior to such termination.  Without derogating from the aforegoing, the provisions of Sections 2.10.2, 2.10.5, 2.10.6, 4,
                    5, 6, 7.4 through this 7.8, 9, 10, 11, and 13 to this Agreement, as well as the provisions of the Quality Agreement and the CDA, shall survive termination of this Agreement.

              

         

        	8.	
                GENERAL REPRESENTATIONS, WARRANTIES AND COVENANTS OF THE PARTIES

              

         

        	8.1	
                Mutual Representations and Warranties.  Each Party represents, warrants and covenants to the other Party
                    that:

              

         

        	

              	8.1.1	
                it has the full right and authority to enter into this Agreement and to perform its obligations hereunder; and

              

         

        	

              	8.1.2	
                neither the execution nor the performance of this Agreement, will result in the violation of statute, regulation or judicial decree, or cause such Party to breach any contractual commitment by which it is
                  bound; and

              

         

        	

              	8.1.3	
                this Agreement constitutes its valid and binding obligation, enforceable against it in accordance with its terms.

              

         

        

        
          Page 24 of 44

          
            

        

        	8.2	
                Tapi Representations and Warranties.

              

         

        	

              	8.2.1	
                TAPI represents and warrants to Chiasma that:

              

         

        	

              	(a)	
                all API shall (i) be manufactured in compliance with cGMP, the Specifications, the Drug Master File and Applicable Law; (ii) be packaged and stored in accordance with the Specifications, Applicable Law and other requirements set out in the Quality Agreement; (iii) be shipped in accordance with the Shipping Guidelines and Quality Agreement; (iv) upon delivery be free from defects in material and
                    workmanship; and the API is not adulterated or misbranded under the U.S. Federal Food, Drug and Cosmetic Act; and

              

         

        	

              	(b)	
                TAPI has not received any notice or claim alleging that the manufacture of the API infringes or misappropriates any intellectual property right of any third party.  TAPI shall promptly notify Chiasma upon
                  becoming aware of any such notice or claim; and

              

         

        	

              	(c)	
                it owns (directly or indirectly, or its Affiliates own) and/or controls the Manufacturing Facility, it has all the necessary permits and licenses to operate the Manufacturing Facility and that the
                  Manufacturing Facility shall be maintained in accordance with cGMP and in such condition as will allow Manufacturer to manufacture the API in compliance with cGMP and the other requirements set out in Section 8.2.1(a) above; and

              

         

        	

              	(d)	
                it has the experience, capability, qualifications, equipment, resources, registrations, approvals and appropriately qualified personnel necessary for the performance of its obligations under this Agreement
                  (including, the technical requirements and timelines set out therein); and

              

         

        	

              	(e)	
                to the best of TAPI’s knowledge, the performance of its obligations under this Agreement does not and shall not conflict with any applicable law or regulation which apply to Manufacturer and/or its
                  employees.

              

         

        	

              	8.2.2	
                Except as specifically set forth in this Agreement, TAPI makes no express or implied warranties, statutory or otherwise, concerning the deliverables or the API.  Without limiting the generality of the
                  foregoing, TAPI makes no implied warranty of merchantability or fitness for a particular purpose regarding the API and/or other deliverables.

              

         

        	8.3	
                Tapi covenants.

              

         

        TAPI covenants to Chiasma as follows:

         

        	

              	8.3.1	
                it will perform its obligations under this Agreement in accordance with Applicable Law; and

              

         

        

        
          Page 25 of 44

          
            

        

        	

              	8.3.2	
                it will perform its obligations hereunder in a professional manner and in accordance with high standards of care and diligence consistent with industry practices; and

              

         

        	

              	8.3.3	
                it shall exercise due care with respect to safety as is necessary in connection with the performance of its obligations hereunder and as is otherwise reasonable and customary for companies engaged in
                  operations similar to those of Manufacturer; and

              

         

        	

              	8.3.4	
                Chiasma Confidential Information and Intellectual Property of Chiasma will be used solely to perform the Manufacturer’s obligations under this Agreement, and that neither it nor its Approved Subcontractors
                  will use any of the aforegoing for any other purpose.

              

         

        	8.4	
                Chiasma Representations and Warranties.

              

         

        Except to the extent that any of the following are the obligations of Manufacturer, Chiasma represents and warrants to TAPI that (a)
          Chiasma has the right, power and authority to grant Manufacturer the license set forth in Section 5.2 above; (b) it or its Affiliates directly
          or indirectly owns and/or controls all necessary Marketing Authorizations and title to all Intellectual Property related to the Finished Product and the Chiasma Property; and (c) it has the capability, expertise and resources to perform its obligations under this Agreement.

         

        Except as specifically set forth in this Section 8.4, Chiasma makes no other warranties express or implied or representations with respect to the API or otherwise.

         

        	8.5	
                Chiasma Covenants.

              

         

        Chiasma covenants to TAPI that it shall comply with Applicable Law in the performance of its obligations hereunder and in handling, marketing and selling of Finished Product.

         

        	9.	
                INDEMNIFICATION; INSURANCE; LIMITATION ON LIABILITY

              

         

        	9.1	
                Indemnification by Chiasma.

              

         

        Chiasma shall indemnify, defend and hold harmless Manufacturer, and Manufacturer’s directors, officers, employees and agents from and against any and all claims, losses, liabilities, lawsuits,
          proceedings, costs and expenses, including reasonable attorneys’ fees, asserted or filed by a third party, (collectively, “Liabilities”) to the extent arising out of or in connection with:

         

        	

              	9.1.1	
                any breach by Chiasma of any covenant, representation, warranty or obligation hereunder; or

              

         

        	

              	9.1.2	
                the violation by Chiasma of Applicable Law; or

              

         

        

        
          Page 26 of 44

          
            

        

        	

              	9.1.3	
                Chiasma’s negligence or willful misconduct in the performance of this Agreement; or

              

         

        	

              	9.1.4	
                Personal or bodily injury (including death) or property damage arising out of any use, distribution or sale by or on behalf of Chiasma of the API and/or the Finished Product;

              

         

        	

              	9.1.5	
                the storage, handling, manufacture, license, use, marketing, advertising, promotion, distribution or sale of the Finished Product by Chiasma or its Affiliates, sublicensees, distributors or agents in the
                  Regions, including, but not limited to, liabilities for product liability and returned goods.

              

         

        	

              	9.1.6	
                any actual or alleged infringement (whether direct, contributory or induced) or violation of any patent, trade secret or proprietary rights of any third party, arising out of Chiasma’s or its Affiliates’
                  and each of their respective officers, directors, agents and employees’ manufacturing, importing, registering, storing, distributing, marketing or selling the Finished Product and/or the API, and in respect of the API, excluding
                  Liabilities caused by TAPI’s gross negligence or willful misconduct.

              

         

        	9.2	
                Indemnification by Tapi.

              

         

        TAPI shall indemnify, defend and hold harmless Chiasma and Chiasma’s Affiliates, and its and their directors, officers, employees and agents from and against any and all Liabilities to the extent
          arising out of or in connection with:

         

        	

              	9.2.1	
                any breach by Manufacturer or any party acting on its behalf (including any Approved Subcontractor) of any covenant, representation, warranty or obligation hereunder; or

              

         

        	

              	9.2.2	
                the violation by Manufacturer of Applicable Law; or

              

         

        	

              	9.2.3	
                any negligence or willful misconduct of Manufacturer, or any party acting on its behalf (including any Approved Subcontractor), in performing any obligations of Manufacturer hereunder.  provided such
                  Liabilities are not related, directly or indirectly, to the use of the API manufactured and delivered in accordance with this Agreement.

              

         

        	9.3	
                Indemnification Procedures.

              

         

        	

              	9.3.1	
                In the event that a Party seeks indemnification (an “Indemnified Party”) under the terms of this
                    Section 9, it shall provide written notice (the “Claim Notice”) to the indemnifying Party (an “Indemnifying Party”) of the claim, lawsuit or other action (a “Claim”)

                    against the Indemnified Party as soon as reasonably practicable after it receives notice thereof, and shall permit the Indemnifying Party, at the Indemnifying Party’s election and cost, to assume the direction and control of the defense
                    of the Claim.

              

         

        

        
          Page 27 of 44

          
            

        

        	

              	9.3.2	
                The Indemnified Party’s failure to notify the Indemnifying Party as set out in Section 9.3.1 above or to take all action reasonably requested by the Indemnifying Party, will not relieve the Indemnifying
                  Party of its obligations under this Section 9, unless and to the extent the Indemnifying Party is prejudiced thereby.

              

         

        	

              	9.3.3	
                After delivery of such Claim Notice, if the Indemnifying Party acknowledges in writing to the Indemnified Party that the Indemnifying Party shall be obligated under the terms of its indemnity
                    hereunder in connection with such Claim, then the Indemnifying Party shall be entitled, if it so elects:  (a) to
                    take control of the defense and investigation of such Claim; (b) to employ and engage attorneys of its own choice to handle and defend the Claim, at the Indemnifying Party’s cost, risk and expense, unless the named parties to such action or proceeding include both the Indemnifying
                    Party and the Indemnified Party and the Indemnified Party has been advised in writing by counsel that there may be one or more legal defenses available to the Indemnified Party that are different from or additional to those available to
                    the Indemnifying Party (in such an event, the Indemnified Party shall bear all costs and expenses incurred by it in connection with the defense of such a Claim); and (c) to compromise or settle such Claim, which compromise or settlement shall not adversely affect the Indemnified
                    Party’s rights under this Agreement or impose any obligations on the Indemnified Party in addition to those set forth herein, or require an admission of liability or wrongdoing by the Indemnified Party without obtaining the prior
                    written consent of such Indemnified Party.  If the Indemnifying Party assumes the defense of a Claim, then it shall not have indemnification obligations with respect to any settlement of any Claim by the Indemnified Party without the
                    prior written consent of the Indemnifying Party.  In addition, the Indemnified Party shall cooperate fully with the Indemnifying Party and its legal representatives in the investigation and defense of any Claim covered by this
                    indemnification, including upon reasonable notice, by having any of its employees, officers, directors, agents and other representatives testify when necessary, and on reasonable notice making available to the Indemnifying Party as
                    necessary all relevant records, specimens, samples and other information in its possession.  The Indemnifying Party shall keep the Indemnified Party reasonably informed of the progress of the defense, compromise or settlement of the
                    Claim.  If the Indemnifying Party assumes the defense of the Indemnified Party as set forth above, the Indemnified Party shall have the right, but not the obligation, to be represented by independent counsel of its own selection,
                    provided that such independent counsel and the cost thereof shall be at Indemnified Party’s sole expense.

              

         

        

        
          Page 28 of 44

          
            

        

        	

              	9.3.4	
                If the Indemnifying Party fails to assume the defense of such Claim within [***] calendar days after receipt of the Claim Notice, the Indemnified Party shall (upon delivering notice to such effect to the
                  Indemnifying Party) have the right to undertake, at the Indemnifying Party’s cost and expense, the defense, compromise or settlement of such Claim on behalf of and for the account and risk of the Indemnifying Party, provided that any
                  settlement or consent judgment shall be subject to the prior written consent of the Indemnifying Party, which shall not be withheld or delayed unreasonably.  In the event the Indemnified Party assumes the defense of the Claim, the
                  Indemnified Party shall keep the Indemnifying Party reasonably informed of the progress of any such defense, compromise or settlement.  Subject to the terms herein, the Indemnifying Party shall be liable for any settlement of any Claim,
                  for any final judgment (subject to any right of appeal), and the Indemnifying Party agrees to indemnify and hold harmless an Indemnified Party from and against any Liabilities by reason of such settlement or judgment, subject to the terms
                  of this Section 9 above.

              

         

        	9.4	
                Insurance.

              

         

        	

              	9.4.1	
                During the term of this Agreement and an extended reporting period of [***] years thereafter, Chiasma shall obtain and maintain the following insurance coverage:

              

         

        Type of Coverage          Amount (US Dollars)

         

        	

              	(a)	
                Commercial General Liability Insurance

              

         

        (excluding products liability coverage)          $[***] per occurrence

         

        	

              	(b)	
                Umbrella Coverage

              

         

        (excluding products liability coverage)          $[***] per occurrence

         

        	

              	(c)	
                Clinical Trial Insurance, as per the requirements of the local law, covering personal injury to a research subject arising out of the clinical trial which is the subject of this Agreement, with limits of liability of not less than
                  US$[***] per occurrence and in the aggregate for the trial.  TAPI shall be included as Additional Insured under the said policy as well as all other parties who involves in the performance of the Trial.  This policy shall be in force
                  until the trial ends and should include an extended reporting period as required by local law or per requirement of local Ethics Committee approving the clinical trial, but not less than [***] years thereafter (unless such insurance is
                  not commercially available).  The policy shall apply retroactively from the beginning of the Trial.

              

         

        	

              	9.4.2	
                Notwithstanding the foregoing, in the event that the API is used for any purpose other than for clinical trials, Chiasma shall, obtain and maintain an appropriate insurance coverage for products liability
                  (for the commercial use, sale or distribution of the Finished Product) for the Agreement Period and if this policy is written on a Claims Made Basis - for additional period of at least [***] years from its termination date, with a minimum
                  limit of liability of $[***] per occurrence and in the aggregate per annual period of $[***], or higher as shall be reasonable and customary in the biopharmaceutical industry for its activities.

              

         

        

        
          Page 29 of 44

          
            

        

        	

              	9.4.3	
                Chiasma shall name TAPI as an additional insured on the insurance specified above with respect to claims arising in connection the clinical trial or marketing covered under the relevant policies.  Chiasma
                  will provide evidence to TAPI of such insurance.  Chiasma will provide written notice of non-renewal, material modification or cancellation of the above insurance policies.

              

         

        	

              	9.4.4	
                “TAPI” for the purpose of the above policies should include Teva API Inc., Teva API By, Teva Pharmaceutical Industries Ltd., Assia Chemical Industries Ltd., Plantex Ltd., Novetide Ltd. and any other TAPI
                  Affiliate which shall be notified in writing to Chiasma.

              

         

        	

              	9.4.5	
                All the above insurance policies shall be primary to any Insurance carried by TAPI.  For clarity, none of the above insurance obligations will reduce TAPI’s obligations, in accordance with this Agreement
                  and in accordance with any law.

              

         

        All the above insurance policies shall be neither cancelled nor restricted unless [***] days’ prior written notice is delivered to TAPI by registered mail.

         

        	9.5	
                Limitation of Liability

              

         

        SAVE FOR ANY LIABILITY FOR BREACH OF SECTIONS 5 (Ownership of Intellectual Property and Proprietary Rights), 6 (Confidentiality), AND 8.3.4 (TAPI’s covenants) ABOVE, AND EXCEPT FOR ANY LIABILITY
          UNDER SECTIONS 9.1 (Indemnification By Chiasma) OR 9.2 (Indemnification by TAPI) ABOVE, NEITHER PARTY SHALL BE LIABLE TO THE OTHER PARTY (WHETHER UNDER CONTRACT, TORT (INCLUDING NEGLIGENCE) OR OTHERWISE), FOR ANY SPECIAL, PUNITIVE, INDIRECT,
          INCIDENTAL OR CONSEQUENTIAL DAMAGES OF ANY KIND, INCLUDING ANY LOSS OR DAMAGE TO BUSINESS EARNINGS, LOST PROFITS OR GOODWILL, SUFFERED BY ANY PERSON OR ENTITY, ARISING OUT OF OR IN CONNECTION WITH THE PERFORMANCE OF THIS AGREEMENT, EVEN IF SUCH
          PARTY IS ADVISED OF THE POSSIBILITY OF SUCH DAMAGES.

         

        	10.	
                DISPUTES; ARBITRATION

              

         

        	10.1	
                Except as provided in Section 10.5 below, or in Section 2.15 above with respect to disputes regarding Non-Complying Products, all disputes, controversies or claims arising out of or relating to the
                  operation or interpretation of this Agreement shall be resolved by arbitration in accordance with the International Rules of the American Arbitration Association before an arbitrator appointed by mutual agreement of the Parties, and
                  failing such agreement within [***] days, the arbitration shall be appointed by the American Arbitration Association.  Any award rendered by the arbitrator shall be in writing, final and binding upon the Parties and judgment upon any such
                  award may be entered in any court having jurisdiction in respect thereof.  The arbitration shall be conducted in the English language in New York, NY, U.S.A.

              

         

        
          Page 30 of 44

          
            

        

        	10.2	
                The arbitrator shall not be bound by the rules of evidence, but be bound to apply the substantive law of the State of New York, U.S.A., and shall be required to give reasons for his/her decision, and except
                  for the purposes of judicial enforcement of an award, the arbitration shall be confidential.

              

         

        	10.3	
                The arbitrator shall be empowered to grant any and all relief that he or she may deem appropriate, including injunctive, interlocutory or other interim relief.

              

         

        	10.4	
                The arbitrator shall award attorneys’ fees and other costs of the arbitration, including the fees and expenses of the arbitrator, to the prevailing Party, as determined by the arbitrator.

              

         

        	10.5	
                Notwithstanding the aforegoing, each of the Parties shall be entitled to apply, pending arbitration, to the competent state and/or federal courts located in New York, NY, U.S.A, or the competent courts
                  located in Tel Aviv-Jaffa, Israel for orders and preliminary or permanent injunctive relief, without bond, to restrain any actual or threatened conduct in violation of this Agreement.

              

         

        	11.	
                GOVERNING LAW

              

         

        This Agreement shall be governed by the laws of the New York, NY, U.S.A., without regard to the principles of conflicts of laws that may direct that the laws of another jurisdiction apply.

         

        	12.	
                FORCE MAJEURE

              

         

        Notwithstanding anything to the contrary contained herein, neither Party shall be liable for any failure or delay on its part in performing any of its obligations under this Agreement, or for any
          loss, damage, costs, charges and expenses incurred or suffered by the other Party by reason thereof, if such failure or delay results from and/or arises out of Force Majeure conditions and provided that the Party claiming Force Majeure shall:  (i) use its commercially reasonable efforts to avoid or remove such cause of non-performance and shall fulfill and continue performance hereunder with
          the utmost dispatch whenever and to the extent such cause or causes are removed or cease to exist; and (ii) shall give notice in writing to the other Party without undue delay after
          such circumstance has occurred.  Upon such notification, the Parties shall agree upon a reasonable extension of the time for performance, not to exceed an extension equal to the period the Force Majeure condition continues to exist.  If an event
          or condition constituting Force Majeure shall continue for more than [***] days, the Parties shall meet to negotiate a mutually satisfactory solution to the problem, if practicable, including, if applicable, the implementation of an agreed upon
          action plan to transfer the manufacture of the API to a manufacturing facility of one of TAPI’s Affiliates or another manufacturing plan.

         

        

        
          Page 31 of 44

          
            

        

        	13.	
                MISCELLANEOUS

              

         

        	13.1	
                Use of Name.  Neither Party shall use the other Party’s name in any marketing, advertising, press release
                    or other promotional literature or any other publicity without the other Party’s prior written consent which shall not be withheld unreasonably, all except for any mention in any applications to any Governmental Authority for regulatory
                    approval, or in the fulfillment of any duty owed to any competent authority (including a duty to make regulatory filings and/or reports) or, in the case of Chiasma, in the presentation of its activities to potential investors, potential
                    business partners and/or collaborators, subject to applicable confidentiality agreements.

              

         

        	13.2	
                Debarment.  Manufacturer has not been debarred under the provisions of the Generic Drug Enforcement Act of
                    1992, including 21 U.S.C.  Section 335a, or under any other Applicable Law or by any other Regulatory Authority.  If at any time during the term of this Agreement Manufacturer:  (a) becomes debarred as aforesaid; or (b) receives notice of action or threat of action with respect to its debarment, Manufacturer shall notify Chiasma thereof in writing immediately.  In the event that
                    Manufacturer becomes debarred as set forth above, this Agreement shall automatically terminate upon receipt of such notice without any further action or notice.  In the event that Manufacturer receives notice of action as set forth in
                    subsection (b) above, Chiasma shall have the right
                    to terminate this Agreement with immediate effect.

              

         

        	13.3	
                Non-Solicitation.  During the term of this Agreement and for a period of [***] thereafter, regardless of
                    the reason for such termination, neither Party shall, directly or indirectly, without the prior written consent of the other Party, solicit or hire, as an employee any person employed by the other Party.

              

         

        	13.4	
                Taxes.  Each Party shall have the sole responsibility for the payment of all taxes and duties imposed upon
                    it by all Governmental Authorities, as they pertain to its duties, obligations and performance under this Agreement.  Without derogating from the aforegoing, if Chiasma is required by Applicable Law to make any tax deduction, tax
                    withholding or similar payment from any amount paid or payable by Chiasma on account of income tax, tax on profit or any other taxes of a similar nature imposed on TAPI, then Chiasma shall deduct the said withholding tax from the
                    payments referred to above, as prescribed by applicable law or at the reduced rate specified in any certificate (if any) furnished to Chiasma by TAPI under any applicable double taxation treaty, and pay such tax to the proper taxation
                    authority, unless TAPI provides Chiasma with evidence of an exemption from the payment of such withholding tax.  Chiasma will deliver to TAPI a statement including the amount of tax withheld and justification therefor, and such other
                    information as may reasonably be necessary for tax credit purposes, and will take all reasonable steps reasonably requested by TAPI and reasonably co-operate with TAPI to assist TAPI in seeking repayment or refund of such withheld
                    taxes.  In such event, the Parties shall discuss in good faith and agree upon the required adjustment of the Fees to reflect the sharing of any additional tax burden between them and if the Parties fail to reach an agreement as
                    aforesaid, TAPI shall be entitled to terminate this Agreement by giving Chiasma [***] months’ written notice of termination, during which [***] month period, TAPI shall continue to supply Chiasma with API in accordance with orders by
                    Chiasma and the additional tax burden shall be shared between the Parties equally, provided that during the last [***] months of such period the Minimum Annual Purchase Requirements shall not apply.

              

         

        
          Page 32 of 44

          
            

        

        	13.5	
                Assignment.  Neither Party may assign this Agreement and the rights and obligations hereunder, without the
                    prior written consent of the other Party, which shall not be unreasonably withheld.  Notwithstanding the aforesaid, either Party may assign this Agreement, upon written notice to the other Party, at its sole discretion and without the
                    prior written consent of the other Party, (i) to an entity that consolidates or merges with or buys all or
                    substantially all of its assets; (ii) to an entity
                    that is an Affiliate; or (iii) with respect to an
                    assignment by Chiasma, to an entity that (a) has received an exclusive license from Chiasma to commercialize the Finished Product; or (b) has acquired from Chiasma all rights and title in and to the Finished Product; or (iv) with respect to an assignment by TAPI, to an entity that
                    has acquired from TAPI all rights and title in and to the API - provided in all cases specified above, that the assignee assumes all responsibilities and obligations of the assigning Party under this Agreement vis-a-vis the other Party.

              

         

        	13.6	
                Waivers.  No waiver by any Party, whether express or implied, of its rights under any provision of this
                    Agreement shall constitute a waiver of such Party’s rights under such provisions at any other time or a waiver of such Party’s rights under any other provision of this Agreement.  No failure by any Party to take any action against any
                    breach of this Agreement or default by another Party shall constitute a waiver of the former Party’s rights to enforce any provision of this Agreement or to take action against such breach or default or any subsequent breach or default
                    by such other Party.

              

         

        	13.7	
                Entire Agreement; Integration.  This Agreement (including the Exhibits hereto) sets forth the entire
                    agreement between the Parties with respect to the subject matter of this Agreement and supersedes all prior discussions, agreements and understandings between the Parties relating to the subject matter hereof including the Agreement
                    dated 26 December 2012 between the Parties.  In the event of any conflict, discrepancy or inconsistency between the terms set forth herein or the terms set forth or referred to in the Quality Agreement, the terms set forth in this
                    Agreement shall control absent a clear indication to the contrary in writing by the Parties, and except with respect to quality issues, which shall be governed by the Quality Agreement.

              

         

        	13.8	
                Modification.  No modification or amendment to this Agreement (including the Exhibits hereto) shall be
                    effective unless set out in a written document signed by the Parties.  Each purchase order for API shall be governed exclusively by the terms and conditions contained herein.

              

         

        	13.9	
                Construction.  Whenever the context may require, the singular form of names and pronouns shall include the
                    plural and vice-versa.  The section and subsection headings are included solely for the convenience of the Parties and shall not
                    be used in the interpretation of this Agreement.  No rule of construction shall apply to this Agreement that construes any language, whether ambiguous, unclear or otherwise, in favor of or against any Party based on the Party that
                    drafted such language.

              

         

        
          Page 33 of 44

          
            

        

        	13.10	
                Severability.  The provisions of this Agreement are severable and, in the event that any court of
                    competent jurisdiction determines that any one or more of the provisions contained in this Agreement shall, for any reason, be held to be invalid, illegal or unenforceable in any respect, such invalidity, illegality or unenforceability
                    shall not affect any other provision of this Agreement; but such provision shall be modified as set out below and the balance of this Agreement shall be interpreted as if such provision were so modified.  The Parties shall negotiate in
                    good faith in order to agree on the terms of an alternative provision which complies with applicable law and achieves, to the greatest extent possible, the same effect as would have been achieved by the invalid, illegal or unenforceable
                    provision.

              

         

        	13.11	
                Counterparts.  This Agreement may be executed in any number of counterparts (including counterparts
                    transmitted by mail, facsimile or by electronic mail in PDF format) and each such counterpart shall be deemed to be an original instrument, but all such counterparts together shall constitute but one agreement.

              

         

        	13.12	
                Relationship Between Parties.  Manufacturer’s relationship with Chiasma shall be that of an independent
                    contractor.  No persons engaged by Manufacturer shall be considered under the provisions of this Agreement or otherwise as an employee of Chiasma.  Nothing contained in this Agreement shall create or imply the creation of a partnership
                    or joint venture between Chiasma and Manufacturer and neither Party shall have any authority (actual or apparent) to bind the other.

              

         

        	13.13	
                Notices.  All notices, requests, consents and other communications (“Notices”) hereunder to either Party shall be made in writing (whether or not specifically required herein) and deemed to be sufficient if contained in a written
                    instrument delivered:  (i) in person or by courier; (ii) duly sent by first class registered or certified mail, postage prepaid; or (iii) by facsimile or e-mail transmission (with written
                    confirmation of receipt, provided that in the event that any notice of termination is sent by electronic mail, such notice shall also be sent in any other manner set out herein).  All Notices shall be addressed to such Party at the
                    address set forth below or such other address as may hereafter be designated in accordance with the provisions of this Section 13.13.  All Notices shall be deemed to have been received on:  (a) the day of delivery, if delivered in person or by courier; (b) [***] days after being mailed by certified or registered mail (for the purposes of proving such service, it being
                    sufficient to prove that such Notice was properly addressed and posted); or (c) the next Business Day after receipt of confirmation of transmission, if sent by facsimile or e-mail transmission.

              

         

        If to Chiasma:

         

        

        Chiasma Inc.

        Attention:  General Counsel

        60 Wells Ave.

        Suite#102

        Newton

        MA 02459, USA

         

        

        
          Page 34 of 44

          
            

        

        Facsimile:  +972 2 571 58 86

        Email:  tara.mccarthy@chiasmapharma.com

         

        Copy to:  Chiasma (Israel) Ltd

        Attn:  Chaime Orlev

        10 Hartom St

        Jerusalem 91450

        POB 45182,

        Israel

        Fax:  +972 2 571 58 86

        Email:  Chaime@chiasmapharma.com

         

        

        
          Page 35 of 44

          
            

        

        If to TAPI:

         

        Teva API, Inc.

        Attention TAPI Inc. President,

        400 Chestnut Ridge Rd.

        Woodcliff, NJ 07677 USA

        Facsimile:  201-307-6909

        Email:  kerri.McCullough@tevapharma.com

         

        Copy to:  Teva Pharmaceutical Industries Ltd. API Division

        Attn:  Nir Koyfman

        5 Basel St

        Petach Tikva

        POB 3190

        Israel

         

        IN WITNESS WHEREOF, the Parties have caused this Agreement to be executed effective of the date first set forth above.

         

        

        	
                TEVA API, INC.

              	 	
                CHIASMA, INC.

              	 
	 	 	 	 
	
                /s/ Kerri Wood

              	 	
                /s/ Mark Leuchtenberger  

                

              	 
	SIGNATURE	 	SIGNATURE	 
	 	 	 	 
	Kerri Wood 

              	 	Mark Leuchtenberger

              	 
	NAME	 	NAME	 
	 	 	 	 
	
                VP, Head of Global TAPI Sales & President, Teva API Inc.

              	 	President & CEO

              	 
	TITLE	 	TITLE	 
	 	 	 	 
	January 6, 2015	 	December 31, 2015

              	 
	DATE	 	DATE	 
	 	 	 	 
	
                 /s/ Kirk Tsahalis

                

              	 	
                

                

              	 
	SIGNATURE	 	
                SIGNATURE

                

              	 
	
                 

                

              	 	
                 

              	 
	Kirk Tsahalis

              	 	 	 
	
                NAME

                

              	 	
                NAME

              	 
	
                 

                

              	 	
                

                

              	 
	
                Associate Director, Sales & Marketing

              	 	

              	 
	TITLE	 	TITLE	 
	 	 	 	 
	January 7, 2016	 	 	 
	
                DATE

              	 	
                DATE

              	 

        

        

        
          Page 36 of 44

          
            

        

        List of Exhibits

          	
                  Exhibit A: 

                  

                	
                  API description

                
	
                  Exhibit B:  

                  

                	
                  CDA

                
	
                  Exhibit C: 

                  

                	
                  API price

                
	
                  Exhibit D:

                	
                  Samples of API

                
	
                  Exhibit E:

                	
                  Quality Agreement

                
	
                  Exhibit F: 

                  

                	
                  Shipping Guidelines

                
	
                  Exhibit G:

                	
                  Long Term Forecast

                
	
                  Exhibit H:

                	
                  Purchase Orders – 2016

                

           

          

        

        
          Page 37 of 44

          
            

        

        EXHIBIT A

         

        API Description

         

        Octreotide acetate, as per the following specifications:

         

        

        
          Page 38 of 44

          
            

        

        EXHIBIT B

         

        CDA

         

          

        
          Page 39 of 44

          
            

        

        MUTUAL CONFIDENTIALITY AND NON-DISCLOSURE AGREEMENT

         

        Made and entered on this 01 day of April. 2008, by and between Chiasma (Israel) Ltd., 9 company registered under the laws of the State of Israel (and any subsidiaries or parent or affiliated companies thereof) of 5
          Ha’Marpe St., Har Hotzvim, Jerusalem, Israel

         

        and

         

        Novetide Lid., a company registered under the laws or the State of Israel of P.O. Box 10140 Haifa Bay, Israel

         

        Whereas the Parties wish to investigate each other’s business and/or products and or technology solely for the purpose of evaluating potential cooperation and or a business relationship between the Parties (the “Permitted Purpose”):  and

         

        Whereas each the Parties will need to be exposed to Confidential Information (as defined below) of the other Party.

         

        NOW THEREFORE. each of the Parties hereby declares, represents. warrants and undertakes towards the other Part as follows.

         

        As used herein the term “Disclosing Pam” shall refer to each of the Parties respectively, and any parent or subsidiaries thereof with respect to any Confidential Information, us defined helms, which such party
          has disclosed, and the term “Receiving Party”, shall refer to each of the Parties respectively. with respect to any
          Confidential Information, as defined below.  Which has been disclosed thereto.  The Disclosing Party and the Receiving Party shall be referred to collectively as the “Parties” and each a “Party”.

         

        	1.	
                Confidential information.  The term “Confidential Information” shall mean any and all information and/or knowledge and/or data, including without limitation, technical, technological,
                  scientific, commercial and/or financial information, whether written, oral, visual, electronic or otherwise in any medium of expression, whether or not marked “Confidential”, regarding or which is related to the Disclosing party, its
                  business, products, technology, operations and/or activities, including without limitation:

              

         

        	(a)	
                inventions, discoveries, developments, improvements, patents, trademarks, copyrights, know-how, design rights, or other forms of protection of industrial and/or intellectual property, whether registered, non-registered or in the
                  process of application, designs, drawings, photographs, models, computer programs, computer codes, specifications, research and development plans, formulae, formulations, methods, experimental works, prototypes, samples, processes,
                  procedures, techniques, protocols and data; and

              

         

        

        
          
            

          2

        

        
        	(b)	
                actual or planned business, development, production, marketing and sale methods, plans and strategies, trade secrets, professional secrets, actual or planned transactions and/or negotiations, business opportunities, prices and pricing
                  methods, employee and managerial training methods and instruction, salaries and employment conditions, details and lists of suppliers, customers, distributors, agents, employees, strategic or business partners and/or services providers,
                  sources, costs, quality control methods, private, municipal and governmental leases, contracts and relationships with business partners or collaborators, licensing and concession agreements, legal and other claims or suits, records,
                  accounting and financial data; and

              

         

        	(c)	
                any other private, confidential and proprietary information relating to any line of business of the Disclosing Party and/or any related entity, whether in Israel or abroad, and any confidential and/or proprietary information of third
                  parties in the possession of the Disclosing Party.

              

         

        The term, “Confidential Information” shall also include all copies, summaries, notes, memoranda, analyses, compilations, studies and other documents and records prepared by or for the Receiving
          Party, to the extent they contain, reflect or are generated by, or based upon, in whole or in part, any Confidential Information.

         

        The obligation of confidentiality hereunder shall not apply in any portion of Confidential Information which the Receiving Party can prove:  (i) is now, or hereafter becomes, generally known to the public, through no act or omission of the Receiving Party, anyone acting on its behalf or of any third party
          owing an obligation of confidentiality and/or non-use towards the Disclosing Party; provided, however, that the information shall not be regarded as generally known if:  (1) the general principle is generally known to the public,
          but the particular idea is not itself public knowledge, in the public domain or so known, or (2) individual components of the information relating to the idea are generally known to the public, but the particular compilation of information is not
          generally known to the public; or (ii) was lawfully and rightfully received by the Receiving Party without restriction as to its use or disclosure, from a third
          parry having a legal right to transmit the same and that is not bound in a confidential relationship with the Disclosing Party or any third party; or (iii) was already in the Receiving Party’s lawful
          possession without restrictions as to its use or disclosure, at the time such information was disclosed by the Disclosing Party to the Receiving Party.

         

        	2.	
                The Receiving Party’s Obligations

              

         

        The Receiving Party hereby undertakes towards the Disclosing Party as follows:

         

        	2.1	
                The Receiving Party shall maintain the Confidential Information in strict and absolute confidence at all times.  The Receiving Party shall not, directly or indirectly, in writing or otherwise, disclose, expose, transfer, use,
                  communicate, disseminate, publish, make available or in any manner reveal, divulge or describe the Confidential Informer ion, in whole or in part, to any person or entity, except as may be expressly authorized in advance in writing by the
                  Disclosing Party or except as may be required to any of the Receiving Party’s employees, officers, directors, advisors, all strictly on a “need-to-know” basis for the Permitted Purpose, and without derogating from the Receiving Party’s
                  responsibility for its employees, representatives and anyone acting on its behalf, only after (i) the Receiving Parry has advised each such employee or anyone acting on its behalf, before s/he receives access to Confidential information
                  of the confidential nature of the Confidential Information and of his/her obligations under this Agreement; and (ii) any such party to whom the Confidential Information is intended to be disclosed has executed a confidentiality
                  undertaking in writing on substantially equivalent terms to this Agreement, eliminating however further disclosures.

              

         

        

        
          
            

          3

        

        The Receiving Party shall take all necessary measures and precautions to safeguard the Confidential Information including. at least those steps that it
          takes to protect its own information of a proprietary and or confidential nature, but no less than a reasonable degree of care. In the event of loss of the Confidential Information or the disclosure of any part thereof by the Receiving Party or
          anyone acting on its behalf, or its coming to the knowledge of any other party, the Receiving Party undertakes, immediately upon becoming aware of the foregoing, to give immediate written notice thereof to the Disclosing Party.

         

        	2.2	
                The Receiving Party shall use the Confidential Information only and safety to the Permitted Purpose and shall not, directly or indirectly, use the Confidential Information for any other purpose whatsoever, nor derive any benefit
                  therefrom.  Any, benefit derived from or relating to the Confidential Information shall belong solely to the Disclosing Party.

              

         

        	2.3	
                The Receiving Party shall not, nor suffer or permit any third party to, analyze, decompile, disassemble, reverse engineer (or the like), any tangible product, material or media which constitutes, contains, records or in any way
                  documents or embodies Confidential Information, and shall not remove, overprint or deface any notice of confidentiality, copyright, trademark, logo, legend or other notices of ownership or
                  confidentiality from any material that contains or embodies Confidential Information.

              

         

        	2.4	
                The Receiving Party shall be responsible towards the Disclosing Party for any disclosure or misuse of Confidential information which results from a failure to comply with this Agreement of it, its employees (including, without
                  limitation, employees, who subsequent to the disclosure of Confidential Information hereunder, become former employees), officers, directors, owners, or any other persons acting on behalf of the Receiving Party.

              

         

        	2.5	
                Notwithstanding the above, the Receiving Party may disclose Confidential Information pursuant to an order of a court of competent jurisdiction or as required by law; provided, however,
                  that (i) the Receiving Party provides the Disclosing Party with adequate prior written notice of such legal requirement and with the opportunity to oppose or limit the disclosure of any such
                  Confidential Information or to seek such protective order(s) or the like as may be available in order to protect the confidentiality of the Confidential Information; and (ii) such disclosure is
                  made only to the limited extent and solely to the recipient legally required.

              

         

        

        
          
            

          4

        

        	3.	
                No license.  The Receiving party acknowledges and recognizes that all Confidential Information made available to, received by, or generated by the Receiving Party, and all right, title and
                  interest therein and thereto, is and shall remain, at all times, the sole and exclusive property of the Disclosing Party, and the Disclosing Party is the sole and exclusive owner and proprietor or the Confidential Information.  This
                  agreement and the furnishing of any Confidential Information hereunder does not constitute and shall not be construed or deemed as granting the Receiving Party, by implication or otherwise, any license, benefit or other right to such
                  Confidential Information and/or to any invention, patent or patent application or trade secrets, now or hereafter owned or controlled by the Disclosing Party.

              

         

        	4.	
                Return of Material.  The Receiving Party shall, upon first written demand by the Disclosing Party, or immediately-upon

                  the termination of the Permitted Purpose, the earlier to occur (i) immediately cease examining and/or using the Confidential Information; and (ii) within [***] days return to the Disclosing Party all documents, materials and samples
                  containing, comprising or embodying the Confidential Information without retaining any copies or samples thereof such that no Confidential Information shall remain with the Receiving Party; and (iii) upon request of the Disclosing Party,
                  certify in writing that it has complied with the obligations set forth in this Section 4.  The delivery to the Disclosing Party of Confidential Information pursuant to this Section 4 shall not derogate from the confidentiality obligations
                  under this Agreement.

              

         

        	5.	
                Disclaimers

              

         

        	5.1	
                The Receiving Party acknowledges that the Disclosing Party makes no express or implied representation or warranty as to the accuracy, completeness or performance of the Confidential Information, which is provided “AS IS”.  The
                  Receiving Party acknowledges that the Confidential Information may still be under development or me be incomplete, and that such information may relate to products or technologies which are under development or are planned for
                  development.  Furthermore, the Receiving Party acknowledges and confirms that the Disclosing Party makes no representation, warranty, assurance, guarantee and/or inducement, express or implied, regarding the merchantability or fitness for
                  a particular purpose, or that the use of the Confidential Information will not infringe any trademarks, patents, copyrights, or any other third party rights.  Neither the Disclosing Party nor any of its officers, directors or employees
                  shall have any liability whatsoever with respect to the use of or reliance upon the Confidential Information by the Receiving Party.

              

         

        	5.2	
                This Agreement does not create an agency, employment, partnership or other business relationship between the Parties, and imposes no obligation on either Party to enter into any business
                  relationship whatsoever with the other Puny.

              

         

        	5.3	
                This Agreement does not create an obligation on the part of the Disclosing Party to disclose any information or Confidential Information.

              

         

        	6.	
                Term and survival.  The obligations and undertakings set forth herein are not limited in time and shall survive the termination or abandonment of any discussions or negotiations and/or
                  cooperation and/or any relationship (all if any) between the Parties, or any other event, and shall remain in full force and effect.

              

         

        

        
          
            

          5

        

        For the avoidance of any doubt, the Receiving Party shall in any event be subject to any patent and or trademark rights and/or any other industrial or intellectual property rights of the
          Disclosing Party.

         

        	7.	
                Equitable Relief.  The Receiving Party acknowledges that the Confidential Information is of a highly secret and confidential nature and that the provisions of this Agreement are necessary
                  for the protection of the business and goodwill of the Disclosing Party and are considered by the Parties to be reasonable for such purpose.  The Receiving Party agrees and acknowledges that any violation or threatened violation of any of
                  its obligations and undertakings contained in this Agreement will result in irreparable and continuing damage or harm to the Disclosing Party for which there will be no adequate remedy at law and that, in addition to any other remedies
                  that may be available in law, in equity or otherwise, the Disclosing Party shall be entitled to obtain injunctive relief against the breach or threatened breach by the Receiving Party of this Agreement, without the necessity of proving
                  actual damages and without derogating from the Disclosing Party’s right to additional remedies, including monetary damages.

              

         

        	8.	
                General

              

         

        	8.1	
                In the event a provision of this Agreement shall be determined to be invalid or unenforceable, the validity of the remaining provisions shall not be affected and the rights and obligations of the Parties shall be construed and
                  enforced, as if the Agreement did not contain the particular provision(s) held to be unenforceable.  In the event the scope and/or duration of one or more of the obligations hereunder exceeds and/or extends the scope and/or duration
                  allowed by law, such obligation shall he deemed to be the maximum scope or duration allowed by law.

              

         

        	8.2	
                The failure by the Disclosing Party to require performance or to enforce any right shall in no manner affect the Disclosing Party’s right at a later time to enforce the same and in no way be construed in be a waiver of such right by
                  the Disclosing Party.

              

         

        	8.3	
                This Agreement constitutes the entire agreement between the Parties with respect to the subject matter hereof and may not be amended except in writing and duly executed by both Parties and supersedes all other understandings or
                  agreements, whether written or oral, between the Parties, with respect to such subject matter.

              

         

        	8.4	
                Neither Party may assign or otherwise transfer this Agreement (or any of its rights or obligations hereunder) to any third party without the prior written consent of the other Party; however, either Party may assign or transfer this
                  Agreement in connection with a merger, acquisition, sale of substantially all its assets or other such corporate reorganization.  Subject to the foregoing, this Agreement shall bind and inure to the benefit of the Parties and their
                  successors and permitted assigns.

              

         

        

        
          
            

          6

        

        	8.5	
                This Agreement, including without limitation, is validity, performance and breach, shall be governed by, and construed in accordance with, the laws of the State of Israel (other than its choice of law rules), and shall be subject to
                  the sole and exclusive jurisdiction of the appropriate courts of competent jurisdiction of Tel Aviv, Israel, to the exclusion or any other courts and jurisdictions and any dispute or claim with respect herein shall be exclusively brought
                  before the appropriate courts of Tel Aviv, Haifa, Israel.  Notwithstanding the foregoing, the Disclosing Party retains the right to institute proceedings including interlocutory and/or injunctive relief in any relevant territory.

              

         

        	8.6	
                This Agreement may be signed by the Parties in counterparts which may be by facsimile signature or scanned signature, each of which when executed and delivered by facsimile transmission, by electronic mail or by mail delivery, will be
                  an original and all of which together will constitute one and the same agreement.

              

         

        	8.7	
                Each Party acknowledges that the other Party’s agreement to furnish it with Confidential Information is based on and is a result of its execution hereof.

              

         

        IN WITNESS WHEREOF the Parties have entered into this Confidentiality and Non-Disclosure Agreement as of the dates written below:

         

        

        	
                /s/ Martin Burg

                

              	 	
                /s/ Avi Tovi

                

              	 
	Chiasma (Israel) Ltd.	 	Novetide Ltd.	 
	 	 	 	 
	
                Name:

                

              	 Martin Burg 	 	
                Name: 

                

              	 Avi Tovi

              	 
	 	 	 	 	 	 
	
                Title:

                

              	 VP Operations 	 	
                Title:

                

              	 CEO

              	 
	 	 	 	 	 	 
	
                Date:

                

              	 April 2, 2008 	 	
                Date:

                

              	 April 2, 2008   

              	 

         

        
          
            

        

        
        EXHIBIT C

         

        API Price

         

        
          Page 39 of 44

          
            

        

        EXHIBIT D

         

        SAMPLES OF API, Prices and Minimum Purchase Obligations

         

          

        
          Page 40 of 44

          
            

        

        EXHIBIT E

         

        Quality Agreement

         

          

        
          Page 41 of 44

          
            

        

        
        API QUALITY AGREEMENT

         

        This API Quality Agreement (“Quality Agreement”) is entered into this 26th day of December 2012 (“Effective Date”)

         

        by and between

         

        Novetide Ltd., a company, having offices at Deshanim Road, Kyriat Ata Israel and, Assia Chemical Industries Ltd., a company, having
          offices at 5 Basel Street, Petach-Tikva 49131 Israel, and manufacturing site at Ramat Hovav, Emek sara, Beer Sheva 84874 Israel.

        (defined together as “Manufacturer”)

         

        and

         

        Chiasma Inc., a company having offices at 831 Beacon St. Suite #313, Newton Center, MA 02459, U.S.A. (“Customer”)

         

        Manufacturer and Customer shall each be referred herein as a “Party” and when referred to jointly as the “Parties”.

         

        WHEREAS, Manufacturer produces active pharmaceutical ingredients at its facilities;

         

        WHEREAS, Manufacturer supplies to Customer, directly or through Manufacturer’s Affiliates, the active pharmaceutical ingredient/s defined in Appendix A attached hereto (“Product”) pursuant to purchase orders issued from time to time by Customer and accepted by Manufacturer subject to the
          terms and conditions of the Manufacturing and Supply Agreement between the Parties dated December 26, 2012 (“the Supply Agreement”);

         

        WHEREAS, Manufacturer and Customer wish to define the individual responsibilities of the Parties as to the quality aspects of manufacturing and release of Product to ensure
          compliance with the approved Product application and/or Customer requirements.

         

        WHEREAS, In order to do so, this Quality Agreement takes the form, in part, of a detailed listing of activities associated with manufacture, supply, production, analysis, and
          release of Product.  Unless otherwise indicated, responsibility for each activity is assigned to either Customer, Manufacturer, or is assigned to both Manufacturer and Customer, as indicated in the listing.

         

        NOW, THEREFORE, in consideration of the Parties’ agreement to perform the activities provided in this Quality Agreement and for other valuable consideration the receipt and
          sufficiency of which is hereby acknowledged, and intending to be legally bound, Manufacturer and Customer agree as provided in this Quality Agreement as follows:

         

        

        
          Page 1 of 44

          
            

        

        	1.	
                Effective Date

              

        The Effective Date of this Quality Agreement shall be the date at first written above, provided that the Quality Agreement has been duly executed by both Parties (the “Effective Date”).

         

        	2.	
                Scope:

              

        This Quality Agreement outlines the responsibilities of Manufacturer and Customer with respect to the quality assurance of the Product manufactured and/or supplied by Manufacturer to Customer (as
          specified in the Preamble of this Quality Agreement).

         

        	3.	
                Interpretation And Definitions

              

         

        	

              	3.1	
                The preamble to this Quality Agreement forms an integral part hereof.

              

         

        	

              	3.2	
                Clause headings in this Quality Agreement are intended solely for convenience of reference and shall be given no effect in the interpretation of this Quality Agreement.

              

         

        	

              	3.3	
                All appendices to this Quality Agreement are attached hereto and incorporated herein by reference.

              

         

        	

              	3.4	
                In this Quality Agreement, unless the contrary intention appears:  (a) the words “including” and “include” mean “including, but not limited to”:  (b) the singular includes the plural and vice versa; (c) a
                  reference to a person or entity (including Manufacturer or Customer) includes a reference to the person’s executors, administrators, successors, substitutes and assigns;

              

         

        	

              	3.5	
                In this Quality Agreement, the following expressions shall bear the meanings assigned to them below and cognate expressions shall bear corresponding meanings:

              

         

        	

              	3.5.1	
                “Affiliates” − with regard to either Party, any person, corporation, company, partnership, joint venture or other entity controlling, controlled by or under common control with such Party.  For such purpose the term
                    “control” means the holding at least filly percent (50%) of the common voting stock or ordinary shares in, or the right to appoint more than fifty percent (50%) of the directors of, or the right to share more than fifty percent (50%) of
                    the profits of, the said corporation, company, partnership, joint venture or entity.

              

         

        	4.	
                Other Agreements

              

         

        This Quality Agreement shall be attached to the Supply Agreement and shall form an integral part thereof.  If there are any direct conflicts between the terms of this Quality Agreement and the
          Supply Agreement with respect to the quality assurance of the Product, this Quality Agreement shall prevail.

          

        

        
          
            

        

        	5.	
                Quality Responsibilities Table

              

         

        The detailed listing of activities associated with manufacture, supply, production, analysis, and release of Product, specifying the binding respective individual responsibilities of the Parties
          is attached hereto as Appendix B.

         

        	6.	
                Product Specifications

              

         

        	

              	6.1	
                Product specifications are listed in Appendix C.

              

         

        	

              	6.2	
                Changes to the agreed upon specifications must be mutually agreed upon and communicated in writing between the Parties to this Quality Agreement, it being agreed that the approval of the relevant Party to
                  any changes as aforesaid should not be withheld unreasonably.

              

         

        	7.	
                Amendments To The Quality Agreement

              

         

        	

              	7.1	
                This Quality Agreement may be amended only by the written consent of both Parties.

              

         

        	

              	7.2	
                The Parties agree to amend terms of this Quality Agreement that must be amended in order that the Product continues to meet regulatory requirements of applicable regulatory agencies, as may exist from time
                  to time.

              

         

        	

              	7.3	
                If an amendment to this Quality Agreement is proposed, the proposing Party will circulate the proposed amendment to the appropriate contact person at Manufacturer and Customer for review and internal
                  approval.  The appropriate contact person at Manufacturer and Customer is listed in Appendix D (Contacts and Responsibilities).

              

         

        	8.	
                Term Of Quality Agreement

              

         

        	

              	8.1	
                This Quality Agreement shall commence on the Effective Date and shall remain in effect for as long as the Manufacturer supplies Product to Customer unless the Quality Agreement is terminated earlier in
                  accordance with the terms of this Quality Agreement.

              

         

        	

              	8.2	
                This Quality Agreement shall terminate automatically upon the termination of the Supply Agreement.

              

         

        
          
            

        

        	9.	
                Use Of Third Parties

              

         

        Manufacturer shall not allow a third party to manufacture, package, label, inspect, test and release Product unless Manufacturer has disclosed in writing to Customer the Manufacturer’s use of a
          third party and in what capacity to which the third party is used and such third party (other than an Affiliate of Manufacturer) has been pre-approved by Customer in writing.  If Manufacturer employs a third party to perform any or part of the
          manufacturing, packaging, labeling, inspection, testing, release and/or handling of Product that is supplied to Customer, Manufacturer shall assure that the third party has been fully qualified via the Manufacturer’s third party qualification
          process prior to performing such activity(ies).  Manufacturer shall, however, retain all obligations under this Quality Agreement whether or not a third party manufactures, packages, labels, inspects, tests, releases and/or handles Product.  If a
          third party is used by Manufacturer to manufacture, package, label, inspect, test, release and/or handle Products, Customer may, upon request, review records and documentation with respect to the services provided by such third party during an
          on-site visit and/or audit pursuant to the Right To Audit section of this Quality Agreement.  Customer agrees to treat such information as Confidential Information of Manufacturer and agrees not to contact any such Parties in connection with this
          Quality Agreement or the product without Manufacturer’s prior written consent.

         

        	10.	
                Reporting

              

         

        	

              	10.1	
                Without derogating from the provisions of Appendix B and section 10.2 below, any material issues or unexpected events relating to the Project or the API, including the manufacture thereof, shall be reported
                  by Manufacturer to Chiasma by telephone or e-mail, as promptly as possible.

              

         

        	

              	10.2	
                Each Party shall use all reasonable efforts, within the timelines set out below, to inform the other Party of:  (i) any pending or threatened litigation, investigation, proceeding or action by any
                  Regulatory Authority or other Governmental Authority, involving the API supplied to Chiasma, of which that Party becomes aware - within [***] Business Days of becoming aware thereof; and (ii) any API which was shipped to Chiasma, or or
                  any component of such API is or may be defective or adulterated or otherwise deviates from the Specifications, within [***] Business Days of becoming aware thereof; and (iii) any safety problem, adverse event, or health care provider
                  complaint, or any other event that would be considered significant by the normal operating standards of the industry and its governing bodies regarding the API, if applicable to the API supplied to Chiasma, within [***] Business Days of
                  becoming aware thereof.

              

         

        	11.	
                Survival Of Regulatory Obligations

              

         

        All regulatory obligations contained herein that are required of either Party or both Parties by an applicable Regulatory Authority shall survive termination of this Quality Agreement.

         

        

        
          
            

        

        	12.	
                Assignment

              

         

        	

              	12.1	
                This Quality Agreement may not be assigned in whole or in part by either of the Parties hereto without the prior written consent of the non-assigning party hereto, which may not be unreasonably withheld. 
                  Such consent may be conditioned upon the agreement of the assigning Party to remain primarily liable for performance of all obligations of the assignee.  Notwithstanding the above, (i) Manufacturer shall be entitled to assign, delegate,
                  and/or subcontract its rights and obligations under this Quality Agreement, in whole or in part, to one or more of its Affiliates on prior written notice to Customer to the appropriate contact person indicated in Appendix D (Contacts and
                  Responsibilities) provided that in the event of an assignment, such Affiliate/s assume/s the responsibilities and obligations of Manufacturer hereunder; and (ii) Customer shall be entitled to assign its rights and obligations under this
                  Agreement, upon written notice to Manufacturer, at its sole discretion and without the prior written consent of Manufacturer, to an entity that:  (i) consolidates or merges with or buys all or substantially all of its assets; or (ii) is
                  an Affiliate of Customer; and (iii) assumes the responsibilities and obligations of Customer hereunder.

              

         

        	

              	12.2	
                In the event of an assignment, the assigning party shall continue to be bound by all preexisting obligations under this Quality Agreement, including all obligations of confidentiality and non-disclosure.

              

         

        	13.	
                Resolution Of Quality Issues

              

         

        Quality related disagreements between Manufacturer and Customer that are not resolved in the normal course of business shall be brought to the attention of the appropriate contact person for
          notices at the Manufacturer and Customer, in writing, as listed in Appendix D (Contacts and Responsibilities).  If both Parties agree that a resolution of the disagreement is reasonably possible, then
          both Manufacturer and Customer shall agree to work jointly to develop a strategy for such resolution.  Manufacturer and Customer further agree to record such resolution in writing.

         

        	14.	
                Debarment

              

         

        Manufacturer warrants and represents that it is not debarred under the Generic Drug Enforcement Act of 1992, 21 U.S.C. 335[a] (the -Generic Drug Enforcement Act”) or under any other applicable law or by any other Regulatory Authority, and that it has not been convicted of a crime for which it could be debarred under the Generic Drug Enforcement
          Act or under any other applicable law or by any other Regulatory Authority.  In connection with the Product, the Manufacturer further warrants and represents, in that it shall not use in any capacity the services of any person debarred under the
          Generic Drug Enforcement Act or under any other applicable law or by any other Regulatory Authority, or convicted of a crime for which a person can be debarred under the Generic Drug Enforcement Act or under any other applicable law or by any
          other Regulatory Authority.

         

        	15.	
                Choice Of Law:  Jurisdiction/ Miscellaneous

              

         

        This Quality Agreement shall be construed and the relationship between the Parties determined in accordance with the laws in the state of Israel without regard to the conflicts of law principals
          thereof.  Any and all disputes between the Parties arising out of or related to this Quality Agreement shall be heard in the competent courts located in Tel-Aviv Israel, and the Parties hereby consent and submit to the exclusive jurisdiction of
          such courts.

         

        

        
          
            

        

        	16.	
                Regulatory Authorities; Approvals

              

         

        Product will be manufactured and tested as registered and approved in the Drug Master File (“DMF”).  Manufacturer shall provide Customer with copies of the open or accessible parts of the DMF and
          all changes thereto as well as copies of all approvals and submissions to Regulatory Authorities, changes thereto and a letter of authorization permitting CHIASMA to refer to the DMF in applications to applicable Regulatory Authorities.  CHIASMA
          shall have the right to use any and all information contained in such approvals, submissions and such parts of the DMF as aforesaid (and any changes thereto, if applicable).

         

        	17.	
                Counterparts

              

         

        This Quality Agreement may be executed in one or more counterparts, each of which will be deemed an original but all of which together will constitute one and the same instrument.  Each
          counterpart transmitted by mail, facsimile or electronic mail shall constitute an original.

         

        IN WITNESS WHEREOF, the undersigned authorized representatives of the respective Parties hereto have entered into and executed this
          Quality Agreement as of the date set forth above.

        	
                MANUFACTURER

              	
                CUSTOMER

              
	 	 
	
                ASSIA CHEMICAL INDUSTRIES LTD.

              	 
	 	 
	
                signature:         

              	/s/ Mariela Betesh	 	
                signature:          

              	 /s/ Shoshie Katz	 
	
                name:          

              	Mariela Betesh	
                name:          

              	 Shoshie Katz
	
                designation: 

                

              	Director of QA, RA	
                designation: 

                

              	 VP QA & RA
	 	 	 	 
	
                signature:          

              	/s/ Evgeney Valdman	 	
                signature:          

              	 /s/ Roni Mamluk	 
	
                name:          

              	Evgeney Valdman	
                name:          

              	 Roni Mamluk
	
                designation: 

                

              	VP, Teva API Division,
                TAPI Israel Manager

              	
                designation: 

                

              	 COO
	 	 
	
                NOVETIDE LTD.

              	 
	 	 
	
                signature:          

              	 /s/ Avi Tovi	 	 
	
                name:          

              	 Avi Tovi	 
	
                designation: 

                

              	 President & CEO, Novetide	 
	 	 
	
                Date:   December 26, 2012

              	
                Date:  January 2, 2013

              

         

        

        
          
            

        

        APPENDIX A:  Definition of Product

         

        “Product” shall mean the following Products:  Octreotide Acetate

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00344-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00344-of-00352.parquet"}]]